

Curriculum Vitae

KARIM ANTON CALIS, PHARM.D, MPH, FASHP, FCCP

PERSONAL INFORMATION

Work Address: National Institutes of Health  
Building 31, Suite 2A25, Room 2A25E  
31 Center Drive (MSC 2423)  
Bethesda, Maryland 20892  
Tel: 301-435-0092  
Fax: 301-480-4473  
E-Mail: [kcalis@nih.gov](mailto:kcalis@nih.gov)

EDUCATION

1995 Master of Public Health  
Bloomberg School of Public Health  
The Johns Hopkins University, Baltimore, MD

1986 Doctor of Pharmacy  
School of Pharmacy  
University of Maryland, Baltimore, MD

1984 Bachelor of Science in Pharmacy  
School of Pharmacy

University of Maryland, Baltimore, MD

1979-1981 Pre-Pharmacy Studies  
University of Maryland, College Park, MD

1979 Maryland High School Diploma  
Robert E. Peary High School, Rockville, Maryland

### **BOARD CERTIFICATION & CREDENTIALING**

Board Certified Pharmacotherapy Specialist (1992-1999)  
Recertified (1999-2006)  
BCPS Number 292219  
Board of Pharmacy Specialties, Washington, DC

Board Certified Nutrition Support Pharmacist (1992-1999)  
Recertified (1999-2006)  
BCNSP Number 392256  
Board of Pharmacy Specialties, Washington, DC

Credentialed in Core Patient Care Privileges (pharmaceutical care)  
Supplemental credentials in Therapeutic Drug Monitoring (TDM), Parenteral Nutrition (PN), and Pain Management, 1999-2001  
Credentialing Committee, NIH Clinical Center

Re-credentialed in Core Privileges, TDM, and PN, 2001-2003  
Re-credentialed in Core Privileges, TDM, and PN, 2003-2005  
Re-credentialed in Core Privileges, TDM, and PN, 2005-2007 Credentialing  
Committee, NIH Clinical Center

### **LICENSURE**

State of Maryland Pharmacy License (1984-Present)  
Maryland Board of Pharmacy, Baltimore, MD

License Number 10264

**PROFESSIONAL EXPERIENCE**

- 2017-Present      Director of Clinical Research and Compliance  
*Eunice Kennedy Shriver* National Institute of Child Health and Human  
Development  
National Institutes of Health, Bethesda, MD
- 2016-Present      Chair, Institutional Review Board  
*Eunice Kennedy Shriver* National Institute of Child Health and Human  
Development  
National Institutes of Health, Bethesda, MD
- 2014-2017      Senior Clinical Analyst  
Clinical Methodology Program  
Office of Medical Policy  
Center for Drug Evaluation and Research  
U.S. Food and Drug Administration
- 2016-2017      Acting Clinical Team Leader  
Division of Clinical Trial Quality  
Office of Medical Policy  
Center for Drug Evaluation and Research  
U.S. Food and Drug Administration
- 2012 (Jun-Sep)    Acting Clinical Team Leader  
Division of Metabolism and Endocrinology Products  
Office of New Drugs  
Center for Drug Evaluation and Research  
U.S. Food and Drug Administration
- 2009-2014      Clinical Reviewer

- Division of Metabolism and Endocrinology Products  
Office of New Drugs  
Center for Drug Evaluation and Research  
U.S. Food and Drug Administration
- 2012-2017      Adjunct Senior Clinical Investigator  
Office of the Clinical Director  
*Eunice Kennedy Shriver* National Institute of Child Health and Human  
Development  
National Institutes of Health, Bethesda, MD
- 2009-2012      Adjunct Senior Clinical Investigator  
Program in Developmental Endocrinology and Genetics  
*Eunice Kennedy Shriver* National Institute of Child Health and Human  
Development  
National Institutes of Health, Bethesda, MD
- 2009-2010      Adjunct Senior Clinical Investigator
- Clinical Endocrinology Branch  
National Institute of Diabetes and Digestive and Kidney Diseases  
National Institutes of Health, Bethesda, MD
- 2007-2016      Vice Chair, Institutional Review Board  
National Institute of Child Health and Human Development  
National Institutes of Health, Bethesda, MD
- 1989-2009      Director, Drug Information Service  
Mark O. Hatfield Clinical Research Center  
National Institutes of Health, Bethesda, MD

- 1989-2009      Clinical Specialist, Endocrinology & Women's Health  
Developmental Endocrinology Branch  
Reproductive Medicine and Biology Branch  
National Institute of Child Health and Human Development (NICHD)  
National Institutes of Health, Bethesda, MD
- Metabolic Diseases Branch  
Clinical Endocrinology Branch  
Diabetes Branch  
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)  
National Institutes of Health, Bethesda, MD
- NICHD/NIDDK Inter-institute Endocrine Service
- 1992-2002      Program Director  
Specialized Residency in Drug Information Practice and  
Pharmacotherapy (ASHP-accredited in Drug Information Practice)  
Warren G. Magnuson Clinical Center  
National Institutes of Health, Bethesda, MD
- 1988-1989      Assistant Director for Clinical Services  
Department of Pharmacy  
Suburban Hospital, Bethesda, MD
- 1987-1989      Director, Nutritional and Metabolic Support  
Suburban Hospital, Bethesda, MD
- 1986-1988      Clinical Coordinator  
Department of Pharmacy  
Suburban Hospital, Bethesda, MD
- 1984-1986      Staff Pharmacist  
Department of Pharmacy Services  
Holy Cross Hospital, Silver Spring, MD

- 1984                      Pharmacist  
Gray Drug Fair (currently Rite Aid Pharmacy)  
Potomac, Maryland
- 1980-1983                Pharmacy Extern  
Peoples Drug Stores (currently CVS Pharmacy)  
Rockville, Maryland

#### ACADEMIC APPOINTMENTS

- 2005-Present            Clinical Professor  
Department of Pharmacotherapy and Outcomes Science  
School of Pharmacy, Medical College of Virginia  
Virginia Commonwealth University, Richmond, VA
- 2003-Present            Clinical Professor  
Department of Pharmacy Practice and Science  
School of Pharmacy  
University of Maryland, Baltimore, MD
- 2003-2006                Clinical Professor  
Department of Pharmacy, School of Pharmacy  
Shenandoah University, Winchester, VA
- 2001-2009                Affiliate Faculty  
Department of Pharmacy Practice  
Idaho State University, Pocatello, ID
- 1998-2003                Clinical Associate Professor  
Department of Pharmacy, School of Pharmacy  
Shenandoah University, Winchester, VA
- 1998-2000                Adjunct Assistant Professor  
Graduate School of Nursing

- 1996-2005      Uniformed Services University of the Health Sciences, Bethesda, MD  
Associate Clinical Professor  
Department of Pharmacy and Pharmaceutics, School of Pharmacy  
Medical College of Virginia  
Virginia Commonwealth University, Richmond, VA
- 1996-2003      Clinical Associate Professor  
Department of Pharmacy Practice and Science, School of Pharmacy  
University of Maryland, Baltimore, MD
- 1987-1996      Clinical Assistant Professor  
Department of Pharmacy Practice and Science, School of Pharmacy  
University of Maryland, Baltimore, MD

#### HONORS, AWARDS, & RECOGNITION

NIH Director's Award (Scientific/Medical Category), National Institutes of Health, June 2015 [Niemann-Pick Disease, type C Collaboration]

Certificate of Appreciation, Faculty for Pharmacy Student Experiential Program, Food and Drug Administration, May 215

NICHD Partnership Award, National Institute of Child Health and Human Development, December 2013 [The citation reads "For outstanding contributions to the NICHD Institutional Review Board"]

Group Recognition Award, Office of the Commissioner Honor Awards, FDA, August 2013

NIH Director's Award (Scientific/Medical Category), National Institutes of Health, June 2013 [Member of the Neimann-Pick Disease, type C Therapeutic Development Team]

Elected Member, Delta Omega National Honor Society in Public Health, May 2012  
[In recognition of "distinguished scholarship and research in public health"]

George F. Archambault Career Achievement Award, U.S. Public Health Service, May 2010  
[The citation reads "For exceptional career achievements in patient care, clinical research, and public health."]

NIH Intramural Bench-to-Bedside Award (Women's Health Category), 2008  
Yanoff LB, Yanovski JA, Cropp C, Chen KY, Calis KA, Savastano D, Han JC, Barak N.  
Histaminergic pathways and energy intake in obese women. [\$100,000/year for two years]

Andrew Craigie Award, Association of Military Surgeons of the United States (AMSUS),  
August 2007 [The citation reads "For outstanding career contributions to clinical research and public health."]

Allen J. Brands Clinical Pharmacist of the Year Award, U.S. Public Health Service, June 2007

Evander Frank Kelly Honored Alumnus Award, School of Pharmacy, University of Maryland, October 2005

Elected, Distinguished Practitioner, National Academies of Practice (DPNAP), July 2004

Award for Excellence in Clinical Pharmacy Practice, Association of Military Surgeons of the United States (AMSUS), August 2002 [The citation reads "For his excellence in clinical pharmacy practice, education, and research."]

Elected, Fellow of the American College of Clinical Pharmacy (FCCP), September 2002

NIH Intramural Bench-to-Bedside Award, 2002  
Parikh SJ, Zmmerberg J, Blank P, Adler-Wailes D, Feng N, Yanovski JA, McDuffie JR, Uwaifa GI, Sebring NG, Calis KA, Reynolds J. Intracellular calcium measurement in adipocytes: an adjunct to the study of supplemental calcium in overweight outpatients (SCOOP Study). [\$100,000/year for two years]

Pharmacy Practice Research Award [\$4,000]  
ASHP Research and Education Foundation, 2001  
Calis KA, Anderson DW, Auth DA, Mays DA, Turcasso NM, Meyer CC, Young LR.



Quality of pharmacotherapy consultations provided by drug information centers in the United States. *Pharmacotherapy* 2000 Jul;20(7):830-6.

Calis KA, Nelson LM, Pastor CL, Wesley RA, Tong ZB, Vanderhoof V, Bakalov V. FSHstimulated inhibin B as a marker for early ovarian insufficiency. Ranked 2<sup>nd</sup> (not funded) in

Women's Health Category, Research Institute Research Awards Program, American College of Clinical Pharmacy, 2001.

Visiting Professor [January 5-20, 2001], Japanese Ministry of Health and Welfare, Selected as part of a group of eight U.S. faculty members to educate Japanese clinicians about applied pharmacotherapy.

Certificate of Appreciation, Japanese Society of Hospital Pharmacists, Presented at Fukuoka University Hospital, Fukuoka, Japan, January 2001.

Certificate of Appreciation, Brazilian Society of Hospital Pharmacy, Salvador, Bahia, Brazil, November 8, 2000.

Elected, Fellow of the American Society of Health-System Pharmacists (FASHP), March 1996

Squibb Leadership Award (1993)

Mckesson Leadership Award (1993)

Hospital Pharmacist of the Year Award (1989)

Washington Metropolitan Society of Hospital Pharmacists

Elected, Outstanding Young Men of America, 1988

Recognition of Excellence (1984)

*Pharmakon* Editor, School of Pharmacy

University of Maryland, Baltimore, MD

Clinical Clerkships Completed with Honors (1984-1986): Ambulatory Care Medicine, Inpatient Medicine (3 different clerkships), and Clinical Research, School of Pharmacy University of Maryland, Baltimore, MD

### **PROFESSIONAL AFFILIATIONS**

American College of Clinical Pharmacy

*Women's Health Practice and Research Network (PRN)*

*Drug Information Practice and Research Network (PRN)*

*Endocrine and Metabolism (PRN)*

American Diabetes Association

*Professional Section*

American Pharmaceutical Association

American Society for Parenteral and Enteral Nutrition

*Research Section*

American Society of Health-System Pharmacists

*Section of Clinical Specialists*

*Drug Information Specialty Practice Group (SPG)*

*Nutrition Support Specialty Practice Group (SPG)*

Association of Military Surgeons of the United States

Chesapeake College of Clinical Pharmacy

Drug Information Association

International Society for Pharmacoepidemiology

Kappa Psi Pharmaceutical Fraternity

League of Intravenous Therapy Education

Maryland Society for Parenteral and Enteral Nutrition

Maryland Society of Health-System Pharmacists

National Academies of Practice

Society for Epidemiologic Research

The Cochrane Collaboration

*Gynaecology and Fertility Group (formerly the Menstrual Disorders & Subfertility Group)*

The Endocrine Society

University of Maryland Alumni Association

Washington Metropolitan Society of Health-System Pharmacists

## PROFESSIONAL ACTIVITIES & APPOINTMENTS

### *Department of Health and Human Services*

Member, Advisory Committee on Development of Hypoglycemia eLearning Tool, Office of Disease Prevention and Health Promotion (ODPHP), 2013-2014

### *Food and Drug Administration*

Member, Drug Safety and Risk Management Advisory Committee, 2019 to Present

Panelist, Part 15 Public Hearing, Confidentiality of Interim Results in Cardiovascular Outcome Safety Trials, August 11, 2014

Project Team Leader, Data Monitoring Committees, Clinical Trials Transformation Initiative, Duke University, June 2014-Present

Bisphenol A (BPA) Joint Emerging Science Working Group, Office of the Commissioner, 2013-2014

DMEP Representative, Visiting Professor Lecture Series (VPLS), 2009 to 2014

External Reviewer, Regulatory Science and Review Enhancement (RSR), 2010

Member, CDER Committee for Advanced Scientific Education (CASE), 2011 to 2014

*Member, Seminar Subcommittee (July 2011 to June 2012 and June 2013 to June 2014)*

*Member, Abrams Award Working Group (2012)*

*Member, Curriculum Subcommittee (July 2012 to June 2013) Chair,*

*Abrams Award Working Group (2013)*

Cardiovascular Endocrine Liaison Program (CELP), Breakout Session, Second Annual Health Professional Organizations Conference, October 4, 2012, FDA White Oak Campus, Silver Spring, Maryland

Presentation to the Endocrinologic and Metabolic Drugs Advisory Committee, Clinical Safety of Insulin Degludec and Insulin Degludec/Insulin Aspart, November 8, 2012

Consultant, Drug Safety and Risk Management Advisory Committee, Center for Drug Evaluation and Research, Food and Drug Administration, 2007-2009

*National Institutes of Health*

NICHD BPCA Work Group, 2018 to Present

NICHD Strategic Planning Working Team, 2018 to Present

Literature Selection Technical Review Committee, National Library of Medicine, 2013-2014

Member, Data and Safety Monitoring Committee, National Institute of Child Health and Human Development — Intrathecal 2-Hydroxypropyl- $\beta$ -Cyclodextrin in Patients with Niemann-Pick Type C1 Disease [13-CH-0001], 2012-Present.

Chair, Data and Safety Monitoring Board, National Institute of Child Health and Human Development — The safety and effectiveness of surgery with or without raloxifene for the treatment of pelvic pain caused by endometriosis [Protocol 99-CH-0012], 1999-2002.

Member, Data and Safety Monitoring Board, National Institute of Arthritis and Musculoskeletal and Skin Diseases — A randomized, third party-blind, placebo-controlled pilot study of the effects of h5G1.1-mAb on dermatomyositis patients [Protocol 00-AR0117], 2000.

Member, Data and Safety Monitoring Board, Craniofacial & Skeletal Diseases Branch, Division of Intramural Research, National Institute of Dental and Craniofacial Research — A randomized, placebo-controlled study of alendronate in the treatment of polyostotic fibrous dysplasia of bone and the McCune-Albright Syndrome [Protocol 98-D-0146], 1999-2001.

Ad Hoc Member, NICHD Data Safety Monitoring Committee, National Institute of Child Health and Human Development, 2002-2009.

Preceptor, Drug Information and Pharmacotherapy, Pharmacy Practice Residency (ASHPaccredited program), Department of Pharmacy, Warren G. Magnuson Clinical Center, National Institutes of Health, Bethesda, MD, 1989-2001.

Co-Chair, Publication and Data Analysis Committee, National Institute of Mental Health — Prevalence of low bone mass and effect of alendronate on bone loss in premenopausal depressed women (The POWER Study) [Protocol 00-M-0203], 2002-2005

Member, Pharmacy and Therapeutics Committee, 1990-2009

Chair, Cytokines Subcommittee, 1991-1996

Chair, Antimicrobials Subcommittee, 1990-2009

Member, Drug Utilization Evaluation Subcommittee

Co-Chair, Drug-Nutrient Interactions Task Force, 1997-2009

Chair, Parenteral Nutrition Task Force, 2001-2002

Antifungals Task Force, 2001

Endocrine/Rheumatology Task Force, 2001

Co-Chair, Nutrition Support Committee, 2002-2004

Member, Scientific Committee, The Menstrual Cycle and Bone Health (Community for Building Healthy Bones), National Institute of Child Health and Human Development, 2002-2009

Symposium Organizing Committee, 1999-2000

The ovary: genesis, function, and failure, Natcher Building and Conference Center, March 30-31, 2000.

Working Group on Pharmacology in Aging and Cancer, National Institute on Aging (NIA), National Cancer Institute (NCI), and Agency for Health Care Policy Research (AHCPR), December 2, 1994.

Member, Institutional Review Board, National Institute of Child Health and Human Development, 1989-Present

Alternate Member, Institutional Review Board, National Institute of Dental Research, 1992-1994

Coordinator, Pharmacy Journal Club

Pharmacology/Toxicology Subcommittee,  
Interagency Animal Model Committee, DHHS, 1990-2005

Editor, *Pharmacy Update*

Intravenous Therapy Task Force, 1992-1994

Administrator, Continuing Education Program, (approved by the Accreditation Council on Pharmacy Education), 1990-2007.

***Suburban Hospital, Bethesda, MD***

Instructor, Diabetes Education Program (ADA-recognized program), 1986-1989

Pharmacy & Therapeutics Committee, 1986-1989

Nutrition Committee, 1986 - 1989

Infection Control Committee, 1986 – 1989

Editor, *Pharmacy Update*

Department of Pharmacy Newsletter, 1986-1989

Hospital Speakers' Bureau, 1987-1989

***University of Maryland, Baltimore, MD***

Coursemaster, Principles of Drug Literature Evaluation (PHNT 506) Spring 1996 and Spring 1997

Preceptor for introduction to clinical practice, drug information, and internal medicine clinical clerkships for doctor of pharmacy students, 1987 - 2009

Educational Advisory Committee, 2005-2009

Chairman, Educational Advisory Committee, 1999-2001

Educational Advisory Committee, 1998-1999

Guest Lecturer, Medical Information Analysis (PHAR 550), 1994-2001.

Founding Editor, *Pharmakon* (1983), School of Pharmacy University of Maryland, Baltimore, MD

***American Society of Health-System Pharmacists, Bethesda, MD***

Drug Information SPG

Research Forum Review Committee

Strategic Planning Committee

Member, Council on Administrative Affairs, 1994-1995

Contributed Papers Review Panel, Midyear and Annual Meetings, 1988-

Meeting Programming Associate/Educational Programming Associate

Team Member and Reviewer, ASHP Clinical Skills Program: Drug Information Series 1993-1994

Member, Committee on Public Policy and Government Relations, Section of Clinical Specialists, 1995

Residency Accreditation Survey Team  
Texas Tech University  
University of Pittsburgh

Reviewer—Fluids, Electrolytes, and Nutrition Section  
Ginsburg DB. ASHP's PharmPrep. Bethesda: American Society of Health-System Pharmacists, 2001.

Reviewer—ASHP Therapeutic Position Statement on the Safe Use of Pharamacotherapy for Obesity Management in Adults. Am J Health-Syst Pharm 2001; 58:1645-55.

*Washington Metropolitan Society of Health-System Pharmacists*  
President (1992-1993)

Chair, Board of Directors (1992-1993)

Programs Committee (1988)

Chairman, Research and Education Committee (1987 - 1990)

*American College of Clinical Pharmacy, Kansas City, MO*  
Chair, Public and Professional Affairs Committee (2001-2002)

Chair-Elect, Women's Health PRN (2001-2002)

Chair, Women's Health PRN (2002-2003)

Abstract Reviewer (1997-2009)

Credentials Committee, 2000-2001



Research Affairs Committee B, 1999-2000

Board Certification Affairs Committee, 1998-1999

Research Affairs Committee, 1997-1998

Spring Research and Practice Forum Program Committee, 1997

Moderator, Updates in Pharmacotherapy – Innovative Therapeutics, 1997

Focus Group Participant, Spring Forum, April 7, 1997

***The United States Pharmacopeial Convention***

Executive Committee of the Council of Experts, 2007-2009

Chair, Endocrinology Expert Committee, 2005-2009

Council of Experts, 2005-2009

Vice Chair, Medicare Model Guidelines Expert Committee, 2005-2009

Medicare Model Guidelines Expert Committee, April 2004-2009

Nutrition and Electrolytes Expert Advisory Panel, 1995-2000.

Endocrinology Expert Committee, 2000-2005

Contributor, *United States Pharmacopeia Dispensing Information (USP DI)*, 1988 - 2004

***Other Organizations***

Member, Women's Health Curriculum Task Force

American Association of Colleges of Pharmacy and FDA Office of Women's Health, 2010

Expert Panel, Improving the Use and Safety of Medications in Women Through Gender and Race Analysis, Agency for Healthcare Research and Quality (AHRQ), April 19-20, 2004.

Pharmaceutical Care Subcommittee, Pharmacy Professional Advisory Committee, United States Public Health Service, 2001-2002

Scientific Program Committee, International Conference on Pharmacoepidemiology, International Society for Pharmacoepidemiology, 1995-

Clinical Consultant (2004-2005)  
Caremark, Inc., Nashville, Tennessee

Pharmacy and Therapeutics Committee (2001-2004) External  
Review Committee (2003-2005)  
AdvancePCS, Minneapolis, MN

Medical and Pharmacy Advisory Board (1997-2001) Advance  
Paradigm, Baltimore, MD

Consultant, "Rx-to-OTC Switch" Project, College of Pharmacy, 1996-1997 University  
of Tennessee, Memphis, TN

Editorial Advisory Board (emergency medicine medical informatics system), Cybermedix,  
Inc., Springfield, VA, 1988-1995

Council of Pharmacists, *Drug Topics*, 1988 - 2009

Research Committee, Holy Cross Hospital, Silver Spring, MD, 1993-1999

Clinical Reviewer and Consultant, Health Information Designs, Inc., Arlington, VA, 1987 –  
199X

Site Coordinator and Participant, Drug Surveillance Network, Center for  
Pharmacoepidemiology Research, State University of New York, Buffalo, NY 1989  
- 1996

Member, Mid Atlantic Pharmacy Cholesterol Council  
National Pharmacy Cholesterol Council

Field Reviewer, Continuing Pharmacy Education Programs American  
Council on Pharmaceutical Education

External Reviewer, Tenure and Promotions  
University of Maryland (Drs. David Mays and Magaly Rodriguez de Bittner)  
Howard University (Dr. Joseph Ofosu)  
Medical University of South Carolina (Dr. Nannette Berensen) St.  
John's University (Dr. Priti Patel)

### ***Community Service***

Volunteer (#0226), Medical Reserve Corps, Office of the County Executive, Montgomery  
County, Maryland, 2005-Present

Member, Parish Council, 2011-2014  
Saint John the Baptist Catholic Community  
Silver Spring, Maryland

### **Reviewer**

*Acta Paediatrica*  
*American Hospital Formulary Service, ASHP*  
*American Journal of Health-System Pharmacy*  
*Annals of Pharmacotherapy*  
*Annals of Internal Medicine*  
*Archives of Internal Medicine*  
*Biopharmaceutics and Drug Disposition*  
*Hospital Formulary*  
*Hospital Pharmacy*  
*Journal of Clinical Endocrinology and Metabolism*  
*Journal of Natural Products*  
*Journal of Parenteral and Enteral Nutrition*  
*Journal of the American Medical Association*

*Journal of the American Pharmacists Association*  
*Nonprescription Drug Therapy: Guiding Patient Self-Care, Facts & Comparisons*  
*Pharmacology for the Primary Care Provider, Mosby*  
*Pharmacotherapy*  
*The Journal of Alternative and Complementary Medicine*  
*The New England Journal of Medicine*  
*United States Pharmacopeia Dispensing Information (USP DI), USP*

### **Editorial Advisory Boards**

- 2008-2009     *The Open Drug Safety Journal*, Bentham Science Publishers
- 2007-2009     *Annals of Pharmacotherapy*  
Women's Health Editorial Panel
- 2005-2008     *Journal of Parenteral and Enteral Nutrition*
- 2002-2009     *Hospital Pharmacy*
- 2000-2003     *The Journal of Alternative and Complementary Medicine*
- 2000-2002     *DrugInfoLine*, American Pharmaceutical Association  
Endocrinologic Disorders Section Advisor
- 2000-2001     *DrugInfoLine*, American Pharmaceutical Association  
Diabetes Care Section Advisor
- 2001-2004     *Journal of the American Pharmaceutical Association*
- 1993-2009     *DRUGDEX System*, Micromedex, Inc.  
Assistant Editor
- 1995-1998     *American Journal of Health-System Pharmacy*

## TEACHING EXPERIENCE

Didactic teaching (guest lecturer) for the University of Maryland and Shenandoah University

Experiential teaching for the University of Maryland, Howard University, Shenandoah University, Virginia Commonwealth University, and others

Guest lecturer in the following nursing pharmacology courses:

- Nurse Practitioner Program, Uniformed Services University of the Health Sciences, Bethesda, MD
- Undergraduate Nursing, Catholic University of America, Washington, D.C.

Clinical analysis of adverse drug reactions, Principles of Clinical Pharmacology Course, Clinical Pharmacology Research Associate Training Program, Warren G. Magnuson Clinical Center, National Institutes of Health; March 18, 1999, March 16, 2000, March 8, 2001, March 7, 2002.

Program Director for the Specialized Residency in Drug Information Practice and Pharmacotherapy.

## RESEARCH EXPERIENCE

*Principal Investigator*

A pilot study of cimetidine-aided creatinine clearance to assess glomerular filtration rate in children, 96-CC-0042

A comparison of chloral hydrate and orally administered midazolam for sedation of pediatric patients undergoing diagnostic imaging procedures (*Study was approved but not initiated because of limited resources*)

Evaluation of the quality of pharmacotherapy consultations provided by U.S. drug information centers (*NIH OHSR deemed this study exempt from IRB consideration*)

*Associate or Co-Investigator*

An open-label phase 3 study of the safety and efficacy of pegvisomant in children with growth hormone excess

Biomarker validation for Neimann-Pick disease, type C: safety and efficacy of n-acetyl cysteine

A pilot study to assess the feasibility of PTH-1-34 therapy via pump in the management of chronic hypoparathyroidism, 08-CH-0203

A Phase II open-label, crossover pharmacokinetic and pharmacodynamic study to compare Chronocort versus Cortef in patients with congenital adrenal hyperplasia

A pilot study evaluating the feasibility of using human parathyroid hormone (1-34) eluting poly(lactic-co-glycolic acid) microspheres for treatment of hypoparathyroidism

Pilot study of the metabolic effects of betahistine hydrochloride in overweight women

Physiologic regulation of fibroblast growth factor-23 (FGF-23), 06-NIDCR-XX

Effect of transdermal estradiol replacement therapy on ovulation rates in women with premature ovarian failure: a randomized, placebo-controlled trial, 06-CH-0201

The role of the orexin system in body weight regulation: patients with narcolepsy, 06-DK0079

Chronic sleep deprivation as a risk factor for metabolic syndrome and obesity, 06-DK-0036

The effects of hydrocortisone, melatonin, and placebo on symptoms of jet lag, 05-CH-0037

Investigation of simvastatin therapy in Smith-Lemli-Opitz syndrome, 03-CH-0225

Study of thyrotropin releasing hormone in normal volunteers and in patients with thyroid or pituitary abnormalities, 03-DK-0098

Supplemental calcium in overweight outpatients (SCOOP Study), 02-CH-0100

Heparin vs. lepirudin flushes in preventing withdrawal occlusion of tunneled, open-ended venous access devices: a blinded, randomized, clinical trial, 02-CC-0203

Assessment of pre- and post-synaptic dopamine function in developmental stuttering using <sup>11</sup>C raclopride and positron emission tomography, 02-DC-0008

Turner Syndrome: hormone replacement therapy, 01-CH-0114

FSH-stimulated inhibin B as a marker for early ovarian insufficiency, 00-CH-0189

The P.O.W.E.R. Study (Premenopause, Osteopenia/ Osteoporosis, Women, Alendronate, Depression): prevalence of low bone mass and effect of alendronate on bone loss in premenopausal depressed women, 00-M-0203

A pilot study of the effects of the aromatase inhibitor letrozole on indices of bone turnover in girls with precocious puberty due to the McCune-Albright Syndrome (*includes a pharmacokinetics study amendment*), 00-D-0183

Hormone replacement in young women with premature ovarian failure (*controlled trial of TMTDS testosterone patch*), 00-CH-0045

Efficacy of leptin replacement in the treatment of lipodystrophy, 00-DK-0146

Effects of metformin on energy intake, energy expenditure, and body weight in overweight children with insulin resistance, 00-CH-0134

Safety and efficacy of orlistat in African American and Caucasian children and adolescents with obesity-related co-morbid conditions, 98-CH-0111

Transdermal androgen replacement therapy for young women with spontaneous premature ovarian failure: a pilot study, 98-CH-0045

The use of metformin to improve fertility in clomiphene-resistant hyperandrogenic anovulation: a double-blinded, placebo-controlled study, 98-CH-0050

Investigation of the human immune response in normal subjects and patients with disorders of the immune system and cancer, 97-C-0143

Effect of diltiazem on renal function in cyclosporine-treated uveitic patients, 97-EI-0179  
Genetic linkage analysis in developmental stuttering: gene mapping in extended kindreds and candidate gene studies, 97-DC-0002

Efficacy of long-term thiazolidinedione therapy in syndromes of severe insulin resistance and lipodystrophy, 97-DK-0203

Ovulation induction in patients with karyotypically normal spontaneous premature ovarian failure

Fadrozole treatment of women to induce formation of multiple preovulatory follicles.

Development of an infusible serum-free medium to support or expand human cells used in gene therapy trials, 1997 (*In vitro, Exempt*)

Efficacy of rosiglitazone or pioglitazone in treatment of lipodystrophy syndrome and nonalcoholic steatohepatitis, 97-DK-0203

Use of advanced nuclear medicine imaging techniques to evaluate drug toxicity in a murine model, 1996 (*Animal, Exempt*)

Cyclodextrin itraconazole in the treatment of oropharyngeal candidiasis in children with HIV infection, 96-C-0041

Use of flutamide in clomiphene-resistant anovulation, 96-CH-0114



An open, randomized, long-term clinical trial of flutamide, testolactone (amendment approved to replace testolactone with letrozole), and reduced hydrocortisone dose vs. conventional treatment of children with congenital adrenal hyperplasia, 96-CH-0033

Treatment trial of oral immunoglobulin in a patient with common variable hypogammaglobulinemia and inflammatory bowel disease, 96-C-0135

Childhood-onset schizophrenia: characterization and treatment with typical and atypical neuroleptics, 96-M-0025

Amphotericin B lipid complex in the treatment of severe mucocutaneous candidiasis: a pilot study, 1995 (*Study was approved but not initiated*)

Regional cerebral blood flow autoregulation in hypertensive cerebrovasculopathy: the efficacy of pharmacological intervention, 95-AG-0022

Childhood onset schizophrenia: an open trial with the atypical neuroleptic olanzapine, 95M-0170

A double-blind trial of pimozide and paroxetine following clomipramine treatment in persons who stutter, 94-DC-0210

Evaluation of 5-fluorouracil-induced cardiotoxicity, 1994 (*Exempt*)

A double-blind, randomized trial of low molecular weight heparin (enoxaparin) to prevent thrombosis related to venous access devices, 94-CC-0136

Low-dose continuous infusions of urokinase with or without heparin to treat fibrinous occlusion of tunneled venous access devices: a randomized, double-blind study, 93-CC0135

Hydroxychloroquine pharmacokinetics in a patient with systemic lupus erythematosus undergoing continuous ambulatory peritoneal dialysis, 1993 (*Exempt*)

Autoimmune premature ovarian failure: a controlled trial of alternate-day prednisone therapy, 92-CH-0223

Ovarian follicle function in patients with premature ovarian failure, 91-CH-0127

Evaluation of the clinical utility of a computerized, patient-driven medication history in the detection and management of adverse drug effects, 1990 (*Exempt*)

IND Applications (co-investigator):

Antalarmin (pending)

N-Acetyl Cysteine for Neimann-Pick Disease Type C

Human parathyroid hormone (two separate INDs)

TMTDS testosterone patch for women (IND 60,587)

Lepirudin for maintenance of catheter patency

Leptin for lipodystrophy

Orlistat for childhood obesity

Metformin for childhood obesity and insulin resistance

Flutamide for ovulation induction in women with PCOS

Letrozole for girls with precocious puberty (IND 60,057)

Simvastatin (oral suspension) in Smith-Lemli-Opitz Syndrome

Thyrotropin releasing hormone (NIH formulation)

### **BOOKS & BOOK CHAPTERS**

Dang DK, Pucino F, Ponte CD, Calis KA. Glucose and Insulin Dysregulation. In: Drug-Induced Diseases: Prevention, Detection, and Management. 3<sup>rd</sup> ed. Tisdale JE, Miller DA, eds. Bethesda: American Society of Health-System Pharmacists; 2018:679-696.

Ness GL, Chen J, Dong BJ, Pucino F, Calis KA. Thyroid Disorders. In: Drug-Induced Diseases: Prevention, Detection, and Management. 3<sup>rd</sup> ed. Tisdale JE, Miller DA, eds. Bethesda: American Society of Health-System Pharmacists; 2018:697-727.

Kalantaridou SN, Borgelt LM, Dang DK, Calis KA. Hormone Therapy in Women. In: Pharmacotherapy: A Pathophysiologic Approach. 10<sup>th</sup> ed. DiPiro JT, Talbert RL, Yee GC, et al., eds. New York: McGraw-Hill Education; 2017:1287-1308.

Jordan JK, Sheehan AH, Calis KA. Pituitary Gland Disorders. In: Pharmacotherapy: A Pathophysiologic Approach. 10<sup>th</sup> ed. DiPiro JT, Talbert RL, Yee GC, et al., eds. New York: McGraw-Hill Education; 2017:1227e.

Sheehan AH, Chen JT, Yanovski JA, Calis KA. Obesity. In: Pharmacotherapy: A Pathophysiologic Approach. 10<sup>th</sup> ed. DiPiro JT, Talbert RL, Yee GC, et al., eds. New York: McGraw-Hill Education; 2017:2385-2402.

Sheehan AH, Calis KA. Hyperprolactinemia. In: Pharmacotherapy Casebook Instructor's Guide. 10<sup>th</sup> ed. Schwinghammer TL, Koehler JM, Borchert JS, Slain D, Park SK, eds. New York: McGraw-Hill Education; 2017:90-1-90-3.

Sheehan AH, Calis KA. Hyperprolactinemia. In: Pharmacotherapy Casebook: A Patient-Focused Approach. 10<sup>th</sup> ed. Schwinghammer TL, Koehler JM, Borchert JS, Slain D, Park SK, eds. New York: McGraw-Hill Education; 2017:239-241.

Calis KA, Sheehan AH. Formulating Effective Responses and Recommendations: A Structured Approach. In: Drug Information: A Guide for Pharmacists. 5<sup>th</sup> ed. Malone PM, Kier KL, Stanovich JE, eds. New York: McGraw-Hill Education; 2014:35-58.

Sheehan AH, Calis KA. Hyperprolactinemia. In: Pharmacotherapy Casebook Instructor's Guide. 9<sup>th</sup> ed. Schwinghammer TL, Koehler JM, eds. New York: McGraw-Hill Education; 2014:90-1-90-3.

Sheehan AH, Calis KA. Hyperprolactinemia. In: Pharmacotherapy Casebook: A Patient-Focused Approach. 9<sup>th</sup> ed. Schwinghammer TL, Koehler JM, eds. New York: McGrawHill Education; 2014:243-245.

Kalantaridou SN, Dang DK, Calis KA. Hormone Therapy in Women. In: Pharmacotherapy: A Pathophysiologic Approach. 9<sup>th</sup> ed. DiPiro JT, Talbert RL, Yee GC, et al., eds. New York: McGraw-Hill Education; 2014:1315-1336.

Jordan JK, Sheehan AH, Yanovski JA, Calis KA. Pituitary Gland Disorders. In: Pharmacotherapy: A Pathophysiologic Approach. 9<sup>th</sup> ed. DiPiro JT, Talbert RL, Yee GC, et al., eds. New York: McGraw-Hill Education; 2014:1237-1252.

Sheehan AH, Chen JT, Yanovski JA, Calis KA. Obesity. In: Pharmacotherapy: A Pathophysiologic Approach. 9<sup>th</sup> ed. DiPiro JT, Talbert RL, Yee GC, et al., eds. New York: McGraw-Hill Education; 2014:2445-2464.

Dang DK, Chen JT, Pucino F, and Calis KA. Adrenal Gland Disorders. In: Pharmacotherapy Principles & Practice. 3<sup>rd</sup> Edition. Chisholm-Burns MA, Wells BG, Schwinghammer TL, et al., eds. New York: McGraw-Hill; 2013:807-823.

Chen JT, Dang JT, Pucino F, and Calis KA. Pituitary Gland Disorders. In: Pharmacotherapy Principles & Practice. 3<sup>rd</sup> Edition. Chisholm-Burns MA, Wells BG, Schwinghammer TL, et al., eds. New York: McGraw-Hill; 2013:825-846.

Sheehan AH, Calis KA. Hyperprolactinemia: the missing period. In: Pharmacotherapy Casebook: A Patient-Focused Approach. 8<sup>th</sup> ed. Schwinghammer TL, Koehler JM, eds. New York: McGraw-Hill; 2011:237-238.

Sheehan AH, Calis KA. Hyperprolactinemia: the missing period. In: Pharmacotherapy Casebook Instructor's Guide. 8<sup>th</sup> ed. Schwinghammer TL, Koehler JM, eds. New York: McGraw-Hill; 2011:89-1 – 89-3.

Calis KA, Sheehan AH. Formulating Effective Responses and Recommendations: A Structured Approach. In: Drug Information: A Guide for Pharmacists. 4<sup>th</sup> ed. Malone PM, Kier KL, Stanovich JE, eds. New York: McGraw-Hill; 2011:35-58.

Chen JT, Sheehan AH, Yanovski JA, Calis KA. Obesity. In: Pharmacotherapy: A Pathophysiologic Approach. 8<sup>th</sup> ed. DiPiro JT, Talbert RL, Yee GC, et al., eds. New York: McGraw-Hill; 2011:2567-2584.

Kalantaridou SN, Dang DK, Davis S, Calis KA. Hormone Therapy in Women. In: Pharmacotherapy: A Pathophysiologic Approach. 8<sup>th</sup> ed. DiPiro JT, Talbert RL, Yee GC, et al., eds. New York: McGraw-Hill; 2011:1417-1436.

Sheehan AH, Yanovski JA, Calis KA. Pituitary Gland Disorders. In: *Pharmacotherapy: A Pathophysiologic Approach*. 8th ed. DiPiro JT, Talbert RL, Yee GC, et al., eds. New York: McGraw-Hill; 2011:1345-1360.

Hansen LB, O'Connell MB, Smith J, Calis KA, eds. *Women's Health Across the Lifespan: A Pharmacotherapeutic Approach*, Bethesda: American Society of Health-System Pharmacists; 2010.

Dang DK, Chen JT, Pucino F, and Calis KA. Adrenal Gland Disorders. In: *Pharmacotherapy Principles & Practice*. 2<sup>nd</sup> Edition. Chisholm-Burns MA, Wells BG, Schwinghammer TL, et al., eds. New York: McGraw-Hill; 2010:685-700.

Chen JT, Dang JT, Pucino F, and Calis KA. Pituitary Gland Disorders. In: *Pharmacotherapy Principles & Practice*. 2<sup>nd</sup> Edition. Chisholm-Burns MA, Wells BG, Schwinghammer TL, et al., eds. New York: McGraw-Hill; 2010:701-720.

Dang D, Fei W, Calis KA. Dysmenorrhea. In: *Women's Health Across the Lifespan: A Pharmacotherapeutic Approach*. 1st ed. Hansen LB, O'Connell MB, Smith J, Calis KA, eds. Bethesda: American Society of Health-System Pharmacists; 2010:181-193.

Kalantaridou S, Lavasidis L, Calis KA. Primary ovarian insufficiency. In: *Women's Health Across the Lifespan: A Pharmacotherapeutic Approach*. 1st ed. Hansen LB, O'Connell MB, Smith J, Calis KA, eds. Bethesda: American Society of Health-System Pharmacists; 2010:225-234.

Chen J, Sheehan AH, Stassinis M, Calis KA. Overweight and obesity. In: *Women's Health Across the Lifespan: A Pharmacotherapeutic Approach*. 1st ed. Hansen LB, O'Connell MB, Smith J, Calis KA, eds. Bethesda: American Society of Health-System Pharmacists; 2010:493-509.

Dang DK, Pucino F, Ponte CD, Calis KA. Glucose and Insulin Dysregulation. In: *Drug-Induced Diseases: Prevention, Detection, and Management*. 2nd ed. Tisdale JE, Miller DA, eds. Bethesda: American Society of Health-System Pharmacists; 2010:571-585.

Chen J, McGriff-Lee N, Pucino F, Dong BJ, Calis KA. Thyroid Disorders. In: Drug-Induced Diseases: Prevention, Detection, and Management. 2nd ed. Tisdale JE, Miller DA, eds. Bethesda: American Society of Health-System Pharmacists; 2010:586-604.

Sheehan AH, Calis KA. Hyperprolactinemia: the missing period. In: Pharmacotherapy Casebook: A Patient-Focused Approach. 7th ed. Schwinghammer TL, Koehler JM, eds. New York: McGraw-Hill; 2009:213-214.

Sheehan AH, Calis KA. Hyperprolactinemia: the missing period. In: Instructor's Guide to Accompany Pharmacotherapy Casebook: A Patient-Focused Approach. 7th ed. Schwinghammer TL, Koehler JM, eds. New York: McGraw-Hill; 2009:85-1—85-3.

Kalantaridou SN, Davis S, Calis KA. Hormone Therapy in Women. In: Pharmacotherapy: A Pathophysiologic Approach. 7th ed. DiPiro JT, Talbert RL, Yee GC, et al., eds. New York: McGraw-Hill; 2008:1351-1368.

Sheehan AH, Yanovski JA, Calis KA. Pituitary Gland Disorders. In: Pharmacotherapy: A Pathophysiologic Approach. 7th ed. DiPiro JT, Talbert RL, Yee GC, et al., eds. New York: McGraw-Hill; 2008:1281-1295.

Dang DK, Chen JT, Pucino F, and Calis KA. Adrenal Gland Disorders. In: Pharmacotherapy Principles & Practice. 1st Edition. Chisholm-Burns MA, Wells BG, Schwinghammer TL, et al., eds. New York: McGraw-Hill; 2008:685-700.

Chen JT, Dang JT, Pucino F, and Calis KA. Pituitary Gland Disorders. In: Pharmacotherapy Principles & Practice. 1st Edition. Chisholm-Burns MA, Wells BG, Schwinghammer TL, et al., eds. New York: McGraw-Hill; 2008:701-720.

Calis KA, Sidawy EN, Young LR. Clinical Analysis of Adverse Drug Reactions. In: Principles of Clinical Pharmacology. 2nd Edition. Atkinson AJ Jr., Abernethy DR, Daniels CE, Dedrick RL, Markey SP, eds. New York: Academic Press; 2006:389-402.

Calis KA, Sheehan AH. Formulating Effective Responses and Recommendations: A Structured Approach. In: Drug Information: A Guide for Pharmacists. 3rd ed. Malone PM, Kier KL, Stanovich JE, eds. New York: McGraw-Hill; 2006:39-59.

Sheehan AH, Calis KA. Hyperprolactinemia. In: Pharmacotherapy Casebook: A Patient-Focused Approach. 6th ed. Schwinghammer TL, ed. New York: McGraw-Hill; 2005:228-230.

Sheehan AH, Calis KA. Hyperprolactinemia. In: Instructor's Guide to Accompany Pharmacotherapy Casebook: A Patient-Focused Approach. 6th ed. Schwinghammer TL, ed. New York: McGraw-Hill; 2005:991-997.

Dang DK, Haines S, Ponte CD, Calis KA. Glucose and Insulin Dysregulation. In: Drug-Induced Diseases: Prevention, Detection, and Management. Tisdale JE, Miller DA, eds. Bethesda: American Society of Health-System Pharmacy; 2005:365-378.

Bethesda: American Society of Health-System Pharmacy; 2005:365-378

McGriff-Lee N, Dong BJ, Pucino F, Calis KA. Thyroid Disorders. In: Drug-Induced Diseases: Prevention, Detection, and Management. Tisdale JE, Miller DA, eds. Bethesda: American Society of Health-System Pharmacy; 2005:379-391.

Kalantaridou SN, Davis S, Calis KA. Hormone Therapy in Women. In: Pharmacotherapy: A Pathophysiologic Approach. 6th ed. DiPiro JT, Talbert RL, Yee GC, et al., eds. New York: McGraw-Hill; 2005:1493-1513.

Sheehan AH, Yanovski JA, Calis KA. Pituitary Gland Disorders. In: Pharmacotherapy: A Pathophysiologic Approach. 6th ed. DiPiro JT, Talbert RL, Yee GC, et al., eds. New York: McGraw-Hill; 2005:1407-1423.

Petrone E, Goldman R, Calis K, Chrousos G, Cizza G. Glucocorticoid-induced osteoporosis: basic mechanisms and clinical implications. Endotext.com [serial online]. 2003. Available at: <http://www.endotext.org/adrenal/adrenal7/adrenal7.htm>.

Calis KA, ed. Encyclopedia of Clinical Pharmacy. Online edition. New York: Marcel Dekker, Inc.; 2002-2003.

Heck AM, Calis KA. Hyperprolactinemia. In: Pharmacotherapy Casebook: A Patient-Focused Approach. 5th ed. Schwinghammer TL, ed. New York: McGraw-Hill; 2002:228-

30.

Heck AM, Calis KA. Hyperprolactinemia. In: Instructor's Guide to Accompany Pharmacotherapy Casebook: A Patient-Focused Approach. 5th ed. Schwinghammer TL, ed. New York: McGraw-Hill; 2002:877-83.

Calis KA, Daniels CE. National Institutes of Health. In: Encyclopedia of Clinical Pharmacy. 1st ed. DiPiro JT, editor. New York: Marcel Dekker, Inc.; 2003:575-9.

Kalantaridou SN, Davis S, Calis KA. Hormone Replacement Therapy. In: Pharmacotherapy: A Pathophysiologic Approach. 5th ed. DiPiro JT, Talbert RL, Yee GC, et al., eds. New York: McGraw-Hill; 2002:1491-1510.

Heck AM, Yanovski JA, Calis KA. Pituitary Gland Disorders. In: Pharmacotherapy: A Pathophysiologic Approach. 5th ed. DiPiro JT, Talbert RL, Yee GC, et al., eds. New York: McGraw-Hill; 2002:1395-1411.

Calis KA, Young LR. Clinical Analysis of Adverse Drug Reactions. In: Principles of Clinical Pharmacology. Atkinson AJ Jr., Daniels CE, Dedrick RL, Grudzinckas CV, Markey SP, eds. New York: Academic Press; 2001:319-32.

Calis KA, Heck AM. Formulating Effective Responses and Recommendations: A Structured Approach. In: Drug Information: A Guide for Pharmacists. 2nd ed. Malone PM, Mosdell KW, Kier KL, et al., eds. New York: McGraw-Hill; 2001:31-51.

Heck AM, Calis KA. Hyperprolactinemia. In: Pharmacotherapy Casebook: A Patient-Focused Approach. 2nd ed. Schwinghammer TL, ed. Stamford: Appleton & Lange; 2000:192-4.

Heck AM, Calis KA. Hyperprolactinemia. In: Instructor's Guide to Accompany Pharmacotherapy Casebook: A Patient-Focused Approach. 2nd ed. Schwinghammer TL, ed. Stamford: Appleton & Lange; 2000:248-51.

Heck AM, Calis KA, Yanovski JA. Pituitary Gland Disorders. In: Pharmacotherapy: A



Pathophysiologic Approach. 4th ed. DiPiro JT, Talbert RL, Yee GC, et al., eds. Stamford: Appleton & Lange; 1999:1281-97.

Mohassel MR, Calis KA. Hair Loss (Alopecia). In: Covington TR, editor. Nonprescription Drug Therapy: Guiding Patient Self-Care. Loose-leaf edition. St. Louis: Facts and Comparisons;1999:146a-146f.

Calis KA and other contributors. Endocrine and Metabolic Disorders. In: Drug Treatment Protocols. Albrant DH, ed. Washington: American Pharmaceutical Association; 1999:4586.

Stager S, Calis K, Grothe D, Bloch M, Turcasso N, Ludlow C, Braun A. A double-blind trial of pimozide and paroxetine for stuttering. In: Speech Production: Motor Control, Brain Research and Fluency Disorders. Hulstijn W, Peters HFM, van Lieshout PHHM, eds. Amsterdam: Elsevier Science Publishers B.V.;1997:371-8.

Calis KA. Establishing and Using a Search Strategy (Unit 2). In: Preparing a Drug Information Response (Module 3), Clinical Skills Program, Drug Information Series. Galt KA, Calis KA, Turcasso NM, eds. Bethesda: American Society of Health-System Pharmacists;1995:25-67.

Calis KA. Selecting Drug Information and Forming Recommendations (Unit 3). In: Preparing a Drug Information Response (Module 3), Clinical Skills Program, Drug Information Series. Galt KA, Calis KA, Turcasso NM, eds. Bethesda: American Society of Health-System Pharmacists;1995:69-86.

Galt KA, Calis KA, Turcasso NM, eds. Preparing a Drug Information Response (Module 3), Clinical Skills Program, Drug Information Series. Bethesda: American Society of HealthSystem Pharmacists;1995.

Calis KA, Brodsky JH, Cooley C, et. al., eds. Manual of Enteral and Parenteral Nutrition, First Edition. Bethesda: Suburban Hospital, Inc.;1990.

Calis, KA, Marchand HC, eds. Formulary of Drugs and Biologics. Bethesda: Suburban Hospital, Inc.;1990.

Calis, KA, Marchand HC, eds. Formulary of Drugs and Biologics. Bethesda: Suburban Hospital, Inc.;1988-1989.

## PUBLICATIONS

Calis KA, Wearne E, Archdeacon P, Chhina M, Sacks L, Hinton D, Temple R, Woodcock J. Safety outcomes trials of FDA-regulated drugs and biologics. (In preparation for N Engl J Med)

Yanovski JA, Calis KA, McDuffie JR, Salaita CG, Tanofsky-Kraff M, et al. A randomized, placebo-controlled trial of the effects of orlistat on body weight and body composition in African American and Caucasian adolescents with obesity-related comorbid conditions. (In preparation for JAMA)

Calis KA, Popat V, Dang DK, Kalantaridou SN, Erogul M. Dysmenorrhea. Medscape Drugs & Diseases. Updated November 2, 2017. Available at:  
<http://emedicine.medscape.com/article/253812-overview>.

Ayeleke RO, Mourad S, Marjoribanks J, Calis KA, Jordan V. Antibiotic prophylaxis for elective hysterectomy. Cochrane Database Syst Rev. 2017 Jun 18;6:CD004637.

Calis KA, Archdeacon P, Bain R, DeMets D, Donohue M, Elzarrad MK, Forrest A, McEachern J, Pencina MJ, Perlmutter J, Lewis RJ. Recommendations for data monitoring committees from the Clinical Trials Transformation Initiative. Clin Trials. 2017 May 1;1740774517707743. doi: 10.1177/1740774517707743. [Epub ahead of print]

Fleming TR, DeMets DL, Roe MT, Wittes J, Calis KA, et al. Data monitoring committees: Promoting best practices to address emerging challenges. Clin Trials. 2017 Apr;14(2):115123. doi: 10.1177/1740774516688915. Epub 2017 Feb 1.

Fleming TR, DeMets DL, Roe MT, Wittes J, Calis KA, et al. Rejoinder. Clin Trials. 2017 Apr;14(2):126-127. doi: 10.1177/1740774516688917. Epub 2017 Jan 31.

Popat V, Hubayter ZR, Calis KA. Gonadotropin-Releasing Hormone Deficiency in Adults. Medscape Drugs & Diseases. Updated January 9, 2017. Available at: <http://emedicine.medscape.com/article/255152-overview>.

Calis KA, Erogul M, Popat V, Kalantaridou SN, Dang DK. Dysmenorrhea. Medscape Drugs & Diseases. Updated October 27, 2016. Available at: <http://emedicine.medscape.com/article/253812-overview>.

Pellegrini VA, Nelson LM, Calis KA. Ovarian Insufficiency. Medscape Drugs & Diseases. Updated November 17, 2016. Available at: <http://emedicine.medscape.com/article/271046overview>.

Lewis RJ, Calis KA, DeMets DL. Enhancing the scientific integrity and safety of clinical trials: recommendations for data monitoring committees from the Clinical Trials Transformation Initiative. JAMA. 2016 Dec 13;316(22):2359-2360.

Calis KA, Archdeacon P, Bain RP, Forrest A, Perlmutter J, DeMets DL. Understanding the functions and operations of data monitoring committees: Survey and focus group findings. Clin Trials. 2017 Feb;14(1):59-66.

Peer CJ, Strobe JD, Beedie S, Ley AM, Holly A, Calis K, Farkas R, Parepally J, Men A, Fadiran EO, Scott P, Jenkins M, Theodore WH, Sissung TM. Alcohol and Aldehyde Dehydrogenases Contribute to Sex-Related Differences in Clearance of Zolpidem in Rats. Front Pharmacol. 2016 Aug 15;7:260.

Wassif CA, Kratz L, Sparks SE, Wheeler C, Bianconi S, Gropman A, Calis KA, Kelley RI, Tierney E, Porter FD. A placebo-controlled trial of simvastatin therapy in Smith-LemliOpitz syndrome. Genet Med. 2017 Mar;19(3):297-305. doi: 10.1038/gim.2016.102.

Sam WJ, Roza O, Hon YY, Alfaro RM, Calis KA, Reynolds JC, Yanovski JA. Effects of SLC22A1 Polymorphisms on Metformin-Induced Reductions in Adiposity and Metformin Pharmacokinetics in Obese Children with Insulin Resistance. J Clin Pharmacol. 2017 Feb;57(2):219-229. doi: 10.1002/jcph.796.

Driscoll MA, Davis MC, Aiken LS, Yeung EW, Sterling EW, Vanderhoof V, Calis KA, Popat V, Covington SN, Nelson LM. Psychosocial vulnerability, resilience resources, and coping with infertility: a longitudinal model of adjustment to primary ovarian insufficiency. *Ann Behav Med.* 2016 Apr;50(2):272-84.

Nelson LM, Calis KA. Management of spontaneous primary ovarian insufficiency (premature ovarian failure). In: *UpToDate*, Post TW (Ed), *UpToDate*, Waltham, MA. (Accessed on August 28, 2015.)

Adeyemo MA, McDuffie JR, Kozlosky M, Krakoff J, Calis KA, Brady SM, Yanovski JA. Effects of metformin on energy intake and satiety in obese children. *Diabetes Obes Metab.* 2015 Apr;17(4):363-70. doi: 10.1111/dom.12426.

Falorni A, Minarelli V, Eads CM, Joachim CM, Persani L, Rossetti R, Beim PY, Pellegrini VA, Schnatz PF, Rafique S, Kissell K, Calis KA, Popat V, Nelson LM. A clinical research integration special program (CRISP) for young women with primary ovarian insufficiency. *Panminerva Med.* 2014;56(4):245-61.

Baid SA, Aguila MMC, Anderson S, Aungst J, Bowyer J, Brown RP, Calis KA, et. al. FDA Bisphenol A (BPA) Joint Emerging Science Working Group, Updated Review of Literature and Data on Bisphenol A (CAS RN 80-05-7), June 6, 2014.

Popat VB, Calis KA, Kalantaridou SN, Vanderhoof VH, Koziol D, Troendle JF, Reynolds JC, Nelson LM. Bone mineral density in young women with primary ovarian insufficiency: results of a three-year randomized controlled trial of physiological transdermal estradiol and testosterone replacement. *J Clin Endocrinol Metab.* 2014 Sep;99(9):3418-26.

Guerrieri GM, Martinez PE, Klug SP, Haq NA, Vanderhoof VH, Koziol DE, Popat VB, Kalantaridou SN, Calis KA, Rubinow DR, Schmidt PJ, Nelson LM. Effects of physiologic testosterone therapy on quality of life, self-esteem, and mood in women with primary ovarian insufficiency. *Menopause.* 2014 Sep;21(9):952-61.

Popat V, Hubayter ZR, Calis KA. Gonadotropin-Releasing Hormone Deficiency in Adults. Medscape Reference. Updated November 11, 2013. Available at:

<http://emedicine.medscape.com/article/255152-overview>.

Calis KA, Dang DK, Popat V, Kalantaridou SN. Dysmenorrhea. Medscape Reference. Updated July 22, 2013. Available at:

<http://emedicine.medscape.com/article/253812overview>.

Popat V, Nelson LM, Calis KA. Ovarian Insufficiency. Medscape Reference. Updated June 17, 2013. Available at: <http://emedicine.medscape.com/article/271046-overview>.

Cizza G, Mistry S, Nguyen VT, Eskandari F, Martinez P, Torvik S, Reynolds JC, Gold PW, Sinai N, Csako G; POWER Study Group. Do premenopausal women with major depression have low bone mineral density? A 36-month prospective study. PLoS One. 2012;7(7):e40894. Epub 2012 Jul 27.

Calis KA. Ulipristal and embryotoxicity—an alternative viewpoint. Pharmacotherapy. 2012 Sep;32(9):e176-7.

Nelson LM, Calis KA. Management of spontaneous primary ovarian insufficiency (premature ovarian failure). In: UpToDate, Basow DS (Ed), UpToDate, Waltham, MA, 2011.

Popat V, Nelson LM, Calis KA. Ovarian Insufficiency. Medscape Reference. October 10, 2011. Available at: <http://emedicine.medscape.com/article/271046-overview>.

Popat V, Hubayter ZR, Calis KA. Gonadotropin-Releasing Hormone Deficiency in Adults. Medscape Reference. June 28 2011. Available at: <http://emedicine.medscape.com/article/255152-overview>.

Calis KA, Popat V, Dang DK, Kalantaridou SN. Dysmenorrhea. Medscape Reference. March 08, 2011. Available at: <http://emedicine.medscape.com/article/253812-overview>.

Yanovski JA, Krakoff J, Salaita CG, McDuffie JR, Kozlosky M, Sebring NG, Reynolds JC, Brady SM, Calis KA. Effects of metformin on body weight and body composition in obese

insulin-resistant children: a randomized clinical trial. *Diabetes*. 2011 Feb;60(2):477-85. Epub 2011 Jan 12.

Schmidt PJ, Luff JA, Haq NA, Vanderhoof VH, Koziol DE, Calis KA, Rubinow DR, Nelson LM. Depression in women with spontaneous 46, XX primary ovarian insufficiency. *J Clin Endocrinol Metab*. 2011 Feb;96(2):E278-87. Epub 2010 Nov 3.

Ali AH, Yanoff LB, Stern EA, Akomeah A, Courville A, Kozlosky M, Brady SM, Calis KA, Reynolds JC, Crocker MK, Barak N, Yanovski JA. Acute effects of betahistine hydrochloride on food intake and appetite in obese women: a randomized, placebocontrolled trial. 2010. *Am J Clin Nutr*. 2010 Dec;92(6):1290-7. Epub 2010 Sep 29.

Cizza G, Nguyen VT, Eskandari F, Duan Z, Wright EC, Reynolds JC, Ahima RS, Blackman MR; POWER Study Group. Low 24-hour adiponectin and high nocturnal leptin concentrations in a case-control study of community-dwelling premenopausal women with major depressive disorder: the Premenopausal, Osteopenia/Osteoporosis, Women, Alendronate, Depression (POWER) study. *J Clin Psychiatry*. 2010 Aug;71(8):1079-87. Epub 2010 May 18.

Naka KK, Kalantaridou SN, Kravariti M, Bechlioulis A, Kazakos N, Calis KA, Makrigiannakis A, Katsouras CS, Chrousos GP, Tsatsoulis A, Michalis LK. Effect of the insulin sensitizers metformin and pioglitazone on endothelial function in young women with polycystic ovary syndrome: a prospective randomized study. *Fertil Steril*. 2011 Jan;95(1):203-9. Epub 2010 Aug 4.

Bechlioulis A, Kalantaridou SN, Naka KK, Chatzikyriakidou A, Calis KA, Makrigiannakis A, Papanikolaou O, Kaponis A, Katsouras C, Georgiou I, Chrousos GP, Michalis LK. Endothelial function, but not carotid intima-media thickness, is affected early in menopause and is associated with severity of hot flashes. *J Clin Endocrinol Metab*. 2010 Mar;95(3):1199-206. Epub 2010 Jan 15.

Bechlioulis A, Naka KK, Calis KA, Makrigiannakis A, Michalis L, Kalantaridou SN. Cardiovascular effects of endogenous estrogen and hormone therapy. *Curr Vasc Pharmacol*. 2010 Mar;8(2):249-58.

Popat V, Nelson LM, Sullivan SD, Calis KA. Amenorrhea, Secondary. Medscape Reference. September 20, 2010. Available at: <http://emedicine.medscape.com/article/276110-overview>.

Wade M, Baid S, Calis K, Raff H, Sinaii N, Nieman L. Technical details influence the diagnostic accuracy of the 1 mcg ACTH stimulation test. *Eur J Endocrinol*. 2010 Jan;162(1):109-13. Epub 2009 Oct 1.

Popat V, Prodanov T, Calis KA, Covington SN, Nelson LM. Amenorrhea, Primary. eMedicine from WebMD. Updated December 15, 2009. Available at: <http://emedicine.medscape.com/article/252928-overview>.

Hubayter ZR, Popat V, Vanderhoof VH, Ndubizu O, Johnson D, Mao E, Calis KA, Troendle JF, Nelson LM. A prospective evaluation of antral follicle function in women with spontaneous 46, XX primary ovarian insufficiency. *Fertil Steril*. 2010 Oct;94(5):1769-74. Epub 2009 Nov 25.

Cizza G, Eskandari F, Coyle M, Krishnamurthy P, Wright EC, Mistry S, Csako G; P.O.W.E.R. (Premenopausal, Osteoporosis Women, Alendronate, Depression) Study Group. Plasma CRP levels in premenopausal women with major depression: a 12-month controlled study. *Horm Metab Res*. 2009 Aug;41(8):641-8. Epub 2009 Apr 30.

Verma S, VanRyzin C, Sinaii N, Kim MS, Nieman LK, Ravindran S, Calis KA, Arlt W, Ross RJ, Merke DP. A pharmacokinetic and pharmacodynamic study of delayed- and extended-release hydrocortisone (Chronocort) versus conventional hydrocortisone (Cortef) in the treatment of congenital adrenal hyperplasia. *Clin Endocrinol (Oxf)*. 2009 May 25. [Epub ahead of print]

Yanovski JA, Parikh SJ, Yanoff LB, Denkinger BI, Calis KA, Reynolds JC, Sebring NG, McHugh T. Effects of calcium supplementation on body weight and adiposity in overweight and obese adults: a randomized trial. *Ann Intern Med*. 2009 Jun 16;150(12):8219, W145-6.

Popat VB, Calis KA, Vanderhoof VH, Cizza G, Reynold JC, Sebring N, Toendle JF, Nelson LM. Bone mineral density in estrogen-deficient young women. *J Clin Endocrinol Metab*. 2009 Apr 28. [Epub ahead of print]

Estes KE, Penzak SR, Calis KA, Walsh TJ. Pharmacology and antifungal properties of anidulafungin, a new echinocandin. *Pharmacotherapy*. 2009 Jan;29(1):17-30.

Calis KA, Popat V, Dang DK, Kalantaridou SN. Dysmenorrhea. *eMedicine from WebMD*. Updated December 18, 2008. Available at:  
<http://emedicine.medscape.com/article/253812overview>.

Popat V, Nelson LM, Calis KA. Amenorrhea, Secondary. *eMedicine from WebMD*. Updated September 19, 2008. Available at:  
<http://emedicine.medscape.com/article/276110overview>.

Popat V, Prodanov T, Calis KA, Verma S, Covington SN, Nelson LM. Amenorrhea, Primary. *eMedicine from WebMD*. Updated August 14, 2008. Available at:  
<http://emedicine.medscape.com/article/252928-overview>.

Popat V, Hubayter ZR, Calis KA. Gonadotropin-Releasing Hormone Deficiency in Adults. *eMedicine from WebMD*. Updated September 7, 2008. Available at:  
<http://emedicine.medscape.com/article/255152-overview>.

Cizza G, Marques AH, Eskandari F, Christie IC, Torvik S, Silverman MN, Phillips TM, Sternberg EM; POWER Study Group. Elevated neuroimmune biomarkers in sweat patches and plasma of premenopausal women with major depressive disorder in remission: the POWER study. *Biol Psychiatry*. 2008 Nov 15;64(10):907-11. Epub 2008 Jul 26.

Popat VB, Prodanov T, Calis KA, Nelson LM. The menstrual cycle: a biological marker of general health in adolescents. *Ann N Y Acad Sci*. 2008 Jun;1135:43-51.

Malozowski S, Nelson LM, Calis KA. More on ovarian insufficiency with imatinib. *N Engl J Med*. 2008 Jun 12;358(24):2648.

Horn TL, Brooks Harder J, Johnson WD, Curry PT, Parchment RE, Morissey RL, Mellick PW, Calis KA, Gold PW, Rice KC, Contoreggi C, Charney DS, Cizza G, Glaze ER, Tomaszewski JE, McCormick DL. Integration of in vivo and in vitro approaches to



characterize the toxicity of antalarmin, a corticotropin-releasing hormone receptor antagonist. *Toxicology*. 2008 Jun 3;248(1):8-17.

Menzie CM, Yanoff LB, Denkinger BI, McHugh T, Sebring NG, Calis KA, Yanovski JA. Obesity-related hypoferrremia is not explained by differences in reported intake of heme and nonheme iron or intake of dietary factors that can affect iron absorption. *J Am Diet Assoc*. 2008;108:145-8.

Popat VB, Vanderhoof VH, Calis KA, Troendle JF, Nelson LM. Normalization of serum luteinizing hormone levels in women with 46,XX spontaneous primary ovarian insufficiency. *Fertil Steril*. 2008 Feb;89(2):429-33. Epub 2007 May 16.

American Society of Health-System Pharmacists. ASHP Statement on the Role of HealthSystem Pharmacists in Public Health. *Am J Health-Syst Pharm*. 2008; 65:462-7.

Eskandari F, Martinez PE, Torvik S, Phillips TM, Sternberg EM, Mistry S, Ronsaville D, Wesley R, Toomey C, Sebring NG, Reynolds JC, Blackman MR, Calis KA, Gold PW, Cizza G. Low bone mass in premenopausal women with depression. *Arch Intern Med*. 2007;167:2329-2336.

Calis KA, Pucino F. Zoledronic acid and secondary prevention of fractures. *N Engl J Med*. 2007 Nov 1;357(18):1861-2.

Kalantaridou SN, Vanderhoof VH, Calis KA, Corrigan EC, Troendle JF, Nelson LM. Sexual function in young women with spontaneous 46,XX primary ovarian insufficiency. *Fertil Steril*. *Fertil Steril*. 2008 Nov;90(5):1805-11. Epub 2007 Oct 25.

Kalantaridou SN, Calis KA. Androgen treatment in women. *Postgrad Obstet Gynecol*. 2007;27:1-8. [reproduced with permission from *Curr Opin Endocrinol Diabetes* 2006]

Feuillan P, Calis K, Hill S, Shawker T, Gehron Robey P, Collins MT. Letrozole treatment of precocious puberty in girls with the McCune-Albright syndrome: a pilot study. *J Clin Endocrinol Metab*. 2007 Jun;92(6):2100-6.

Armstrong A, Calis KA, Nelson LM. Do survivors of childhood cancer have an increased incidence of primary ovarian insufficiency? *Nat Clin Pract Endocrinol Metab.* 2007 Apr;3(4):326-7.

Ventura JL, Fitzgerald OR, Koziol DE, Covington SN, Vanderhoof VH, Calis KA, Nelson LM. Functional well-being is positively correlated with spiritual well-being in women with spontaneous premature ovarian failure. *Fertil Steril.* 2007 Mar;87(3):584-90.

Williams RL, Abernethy DR, Bielory L, Blum RS, Braden NJ, Calis KA, et al. Narrative review: The U.S. Pharmacopeia and model guidelines for Medicare Part D formularies. *Ann Intern Med* 2006;145:448-453.

Kalantaridou SN, Calis KA, Vanderhoof VH, Bakalov VK, Corrigan EC, Troendle JF, Nelson LM. Testosterone deficiency in young women with 46,XX spontaneous premature ovarian failure. *Fertil Steril* 2006;86:1475-1482.

Calis KA, Pucino F, Penzak SR, Lombardo FA. Comment: pharmacist critique was illinformed. *Ann Pharmacother* 2006;40:1697-1698.

Horne MK, McCloskey DJ, Calis K, Wesley R, Childs R, Kasten-Sportes C. Use of heparin versus lepirudin flushes to prevent withdrawal occlusion of central venous access devices. *Pharmacotherapy.* 2006;26:1262-1267.

Kalantaridou SN, Calis KA. Androgen treatment in women. *Curr Opin Endocrinol Diabetes* 2006;13:284-290.

Calis KA, Popat V, Kalantaridou SN, Alzubaidi, N. Dysmenorrhea. eMedicine from WebMD. Updated May 9, 2006. Available at: <http://www.emedicine.com/med/topic606.htm>. Accessed May 9, 2006.

Popat V, Calis KA, Anasti JN, Cackovic, M. Gonadotropin-Releasing Hormone Deficiency in Adults. eMedicine from WebMD. Updated June 14, 2006. Available at: <http://www.emedicine.com/med/topic1342.htm>. Accessed June 14, 2006.

Taylor ED, Theim KR, Mirch MC, Ghorbani S, Tanofsky-Kraff M, Adler-Wailes DC, Brady S, Reynolds JC, Calis KA, Yanovski JA. Orthopedic complications of overweight in children and adolescents. *Pediatrics* 2006;117:2167-2174.

Lee S, Jusko WJ, Salaita CG, Calis KA, Jann MW, Spratlin VE, Goldstein JA, Hon YY. Reduced methylprednisolone clearance causing prolonged pharmacodynamics in a healthy subject was not associated with homozygous CYP3A5\*3 allele or a change in diet composition. *J Clin Pharmacol* 2006;46:515-526.

Kalantaridou SN, Calis KA. Testosterone therapy in premenopausal women. *Semin Reprod Med* 2006;24:106-114.

Hartman JM, Berger A, Baker K, Bolle J, Handel D, Mannes A, Pereira D, St Germain D, Sonbolian N, Ronsaville D, Torvik S, Calis KA, Phillips TM, Cizza G. Quality of life and pain in premenopausal women with major depressive disorder: The POWER Study. *Health Qual Life Outcomes* 2006;4:2.

Pastor CL, Vanderhoof VH, Lim LCL, Calis KA, Premkumar A, Guerrero NT, Nelson LM. Pilot study investigating the age-related decline in ovarian function of regularly menstruating normal women. *Fertil Steril* 2005;84:1462-9.

Stager SV, Calis K, Grothe D, Bloch M, Berensen NM, Smith PJ, Braun A. Treatment with medications affecting dopaminergic and serotonergic mechanisms: Effects on fluency and anxiety in persons who stutter. *J Fluency Disord* 2005;30:319-35.

Kalantaridou SN, Calis KA, Mazer NA, Godoy H, Nelson LM. A pilot study of an investigational testosterone transdermal patch system in young women with spontaneous premature ovarian failure. *J Clin Endocrinol Metab* 2005;90:6549-52.

Bakalov VK, Anasti JN, Calis KA, Vanderhoof VH, Premkumar A, Chen S, Furmaniak J, Smith BR, Merino MJ, Nelson LM. Autoimmune oophoritis as a mechanism of follicular dysfunction in women with 46,XX spontaneous premature ovarian failure. *Fertil Steril* 2005;84:958-65.

Groff AA, Covington SN, Halverson LR, Fitzgerald OR, Vanderhoof V, Calis K, Nelson LM. Assessing the emotional needs of women with spontaneous premature ovarian failure. *Fertil Steril* 2005;83:1734-41.

Petraitis V, Petraitiene R, Lin P, Calis K, Kelaher AM, Muray HA, Mya-San C, Mickiene D,<sup>1</sup> Bacher J, Walsh TJ. Efficacy and safety of generic amphotericin B in experimental pulmonary aspergillosis. *Antimicrob Agents Chemother* 2005;49:1642-1645.

McGriff-Lee N, Kalantaridou SN, Pucino F, Calis KA. Effects of androgens on bone in men and women. *Clin Rev Bone Miner Metab* 2005; 3:51-66.

Bielory L, Williams RL, Abernethy DR, Blum RS, Braden NJ, Calis KA, et al. United States Pharmacopeia development of the Medicare model formulary guidelines. *Am J Geriatr Cardiol* 2005 Nov-Dec;14(6):301-7.

Calis KA, Pucino F, Restrepo ML. Pharmacists and emergency contraception. *N Engl J Med* 2005;352:942-4.

Ayala AR, Pushkas J, Higley JD, Ronsaville D, Gold PW, Chrousos GP, Pacak K, Calis KA, Gerald M, Lindell S, Rice KC, Cizza G. Behavioral, adrenal, and sympathetic responses to long-term administration of an oral corticotropin-releasing hormone receptor antagonist in a primate stress paradigm. *J Clin Endocrinol Metab* 2004;89:5729-37.

Calis KA, Pucino F. Emergency contraception: the right to full disclosure. *Am J HealthSyst Pharm* 2004;61:2011.

McDuffie JR, Riggs PA, Calis KA, Freedman RJ, Oral EA, DePaoli AM, Yanovski JA. Effects of exogenous leptin on satiety and satiation in patients with lipodystrophy and leptin insufficiency. *J Clin Endocrinol Metab* 2004;89:4258-4263.

Calis KA, Hutchison LC, Elliott ME, Ives TJ, Zillich AJ, Poirier T, Townsend KA, Woodall B, Feldman S, Raebel MA. ACCP White Paper. Healthy People 2010: challenges, opportunities, and a call to action for America's pharmacists. *Pharmacotherapy* 2004;24:1241-1294.

Kalantaridou SN, Naka KK, Papanikolaou E, Kazakos N, Kravariti M, Calis KA, Paraskevaïdis EA, Sideris DA, Tsatsoulis A, Chrousos GP, Michalis LK. Impaired endothelial function in young women with premature ovarian failure: normalization with hormone therapy. *J Clin Endocrinol Metab* 2004;89:3907-3913

Calis KA, Young LR. Clinical analysis of adverse drug reactions: a primer for clinicians. *Hosp Pharm* 2004;39:697-712.

McDuffie JR, Calis KA, Uwaifo GI, Sebring NG, Fallon EM, Frazer TE, Van Hubbard S, Yanovski JA. Efficacy of orlistat as an adjunct to behavioral treatment in overweight African American and Caucasian adolescents with obesity-related co-morbid conditions. *J Pediatr Endocrinol Metab* 2004;17:307-319.

Smith JA, Vitale S, Reed GF, Grieshaber SA, Goodman LA, Vanderhoof VH, Calis KA, Nelson LM. Dry eye signs and symptoms in women with premature ovarian failure. *Arch Ophthalmol* 2004;122:151-156.

Kintzel PE, Eastlund T, Calis KA. Extracorporeal removal of antimicrobials during plasmapheresis. *J Clin Apheresis* 2003;18(4):194-205.

Nunez SB, Calis K, Cutler GB Jr, Jones J, Feuïllan PP. Lack of efficacy of fadrozole in treating precocious puberty in girls with the McCune-Albright syndrome. *J Clin Endocrinol Metab* 2003;88(12):5730-3.

Marjoribanks J, Calis KA, Jordan V. Antibiotic prophylaxis for elective hysterectomy. *Cochrane Database of Systematic Reviews* 2004, Issue 1. Art. No.: CD004637. DOI: 10.1002/14651858.CD004637.

Uwaifo GI, Fallon EM, Calis KA, Drinkard B, McDuffie JR, Yanovski JA. Improvement in hypertrophic cardiomyopathy after significant weight loss: case report. *South Med J* 2003;96(6):626-31.

Roden MM, Nelson LD, Knudsen TA, Jarosinski PF, Starling JM, Shiflett SE, Calis K, DeChristoforo R, Donowitz GR, Buell D, Walsh TJ. Triad of acute infusion-related

reactions associated with liposomal amphotericin B: analysis of clinical and epidemiological characteristics. *Clin Infect Dis* 2003;36(10):1213-20.

McDuffie JR, Calis KA, Booth SL, Uwaifo GI, Yanovski JA. Effects of orlistat on fat-soluble vitamins in obese adolescents. *Pharmacotherapy* 2002;22(7):814-22.

McDuffie JR, Calis KA, Uwaifo GI, Sebring NG, Fallon EM, Hubbard VS, Yanovski JA. Three-month tolerability of orlistat in adolescents with obesity-related comorbid conditions. *Obes Res* 2002;10:642-50.

Gahl WA, Brantly M, Troendle J, Avila NA, Padua A, Montalvo C, Cardona H, Calis KA, Gochuico B. Effect of pirfenidone on the pulmonary fibrosis of Hermansky-Pudlak Syndrome. *Mol Genet Metab* 2002;76:234-42.

Charmandari E, Calis KA, Keil MF, Mohassel MR, Remaley A, Merke DP. Flutamide decreases cortisol clearance in patients with congenital adrenal hyperplasia. *J Clin Endocrinol Metab* 2002;87:3197-200.

Heck AM, Calis KA, McDuffie JR, Carobene SE, Yanovski JA. Additive gastrointestinal effects with concomitant use of olestra and orlistat. *Ann Pharmacother* 2002;36:1003-5.

Alzubaidi NH, Chapin HL, Vanderhoof VH, Calis KA, Nelson LM. Meeting the needs of young women with secondary amenorrhea and spontaneous premature ovarian failure. *Obstet Gynecol* 2002;99:720-5.

Wright LJ, Kalantaridou SN, Calis KA. Update on the benefits and risks of hormone replacement therapy. *Formulary* 2002;37(2):78-93.

Alzubaidi N, Calis KA, Nelson LM. Dysmenorrhea. *eMedicine Journal* [serial online]. 2003. Available at: <http://www.emedicine.com/med/topic606.htm>.

Krakoff J, Koch CA, Calis KA, Alexander RH, Nieman LK. Use of a parenteral propylene glycol-containing etomidate preparation for the long-term management of ectopic Cushing's syndrome. *J Clin Endocrinol Metab* 2001;86:4104-8.

Kalantaridou SN, Calis KA, Nelson LM. Immune modulation therapy for autoimmune ovarian failure. (Protocol) *Cochrane Database of Systematic Reviews* 2001, Issue 4. Art. No.: CD003358. DOI: 10.1002/14651858.CD003358.

Kalantaridou SN, Calis KA, Nelson LM. Ovulation induction in women with spontaneous premature ovarian failure. (Protocol) Cochrane Database of Systematic Reviews 2001, Issue 4. Art. No.: CD003355. DOI: 10.1002/14651858.CD003355.

Kalantaridou SN, Calis KA, Nelson LM. Hormone replacement therapy in young women with karyotypically normal spontaneous premature ovarian failure. (Protocol) Cochrane Database of Systematic Reviews 2001, Issue 4. Art. No.: CD003356. DOI: 10.1002/14651858.CD003356.

Calis KA, Daniels CE. Safety reporting in clinical trials. *JAMA* 2001;285(16):2076.

Merke DP, Cho D, Calis KA, Keil MF, Chrousos GP. Hydrocortisone suspension and hydrocortisone tablets are not bioequivalent in the treatment of children with congenital adrenal hyperplasia. *J Clin Endocrinol Metab* 2001; 86: 441-5.

Ellahham SH, Charlton V, Abassi Z, Calis KA, Choucair WK. Bosentan and the endothelin system in congestive heart failure. *Clin Cardiol* 2000;23:803-7.

Calis KA, Anderson DW, Auth DA, Mays DA, Turcasso NM, Meyer CC, Young LR. Quality of pharmacotherapy consultations provided by drug information centers in the United States. *Pharmacotherapy* 2000 Jul;20(7):830-6.

Semba CP, Bakal CW, Calis KA, Grubbs GE, Hunter DW, Matalon TA, Murphy TP, Stump DC, Thomas S, Warner DL. Alteplase as an alternative to urokinase. *J Vasc Interv Radiol* 2000;11(3):279-87.

Grothe DR, Calis KA, Jacobsen L, Kumra S, DeVane CL, Rapoport JL, Bergstrom RF, Kurtz DL. Olanzapine pharmacokinetics in pediatric and adolescent inpatients with childhood-onset schizophrenia. *J Clin Psychopharmacol* 2000;20:220-5.

Heck AM, Yanovski JA, Calis KA. Orlistat, a new lipase inhibitor for the management of obesity. *Pharmacotherapy* 2000;20(3):270-9.

Semba CP, Murphy TP, Bakal CW, Calis KA, Matalon TA. Thrombolytic therapy with use of alteplase (rt-PA) in peripheral arterial occlusive disease: review of the clinical literature. *J Vasc Interv Radiol* 2000;11(2):149-61.

Calis KA, Cullinane AM, Horne MK. Bioactivity of cryopreserved alteplase solutions. *Am J Health-Syst Pharm* 1999; 56:2056-7.

Masucci IP, Calis KA, Bartlett DL, et al. Thrombocytopenia after isolated limb or hepatic perfusions with melphalan: the risk of heparin-induced thrombocytopenia. *Ann Surg Oncol* 1999; 6(5):476-80.

Bloch M, Stager S, Braun A, Calis KA, Turcasso NM, Grothe DR, Rubinow DR. Pimozide-induced depression in men who stutter. *J Clin Psychiatry* 1997;58(10):433-6.

Meyer CC, Calis KA, Burke LB, Walawander CA, Grasela TH. Symptomatic cardiotoxicity associated with 5-fluorouracil. *Pharmacotherapy* 1997;17(4):729-36.

Meyer CC, Calis KA. New hemodialysis membranes and vancomycin clearance. *Am J Health-Syst Pharm* 1995;52:2794-6.

Mays DA, Calis KA. EMLA cream for topical local anesthesia. *Journal of Pharmaceutical Care in Pain & Symptom Control* 1994;2(4):15-21.

Paradis J, Calis KA. Zidovudine-associated myopathy. *Am J Hosp Pharm* 1994;51:3026-8.

Figg WD, Thibault A, Sartor AO, Mays D, Headlee D, Calis KA, Cooper MR. Hypothyroidism associated with aminoglutethimide in patients with prostate cancer. *Arch Intern Med* 1994;154:1023-25.

Freid KM, Calis KA. Growth hormone as an adjunct to parenteral nutrition. *Am J Hosp Pharm* 1994; 51:2244-8.

DeLeo JM, Pucino F, Calis KA, Crawford KW, Gallelli JF. Patient-interactive computer system for obtaining medication histories. *Am J Hosp Pharm* 1993;50:2348-52.



Goldspiel BR, Green L, Calis KA. Human gene therapy. Clin Pharm 1993 Jul;12:488-505.

Yurkowski PJ, Calis KA. Erythromycin, motilin, and gastroparesis. Clin Pharm 1992 Nov;11(11):917-8.

Corso DM, Pucino F, DeLeo JM, Calis KA, Gallelli JF. Development of a questionnaire for detecting potential adverse drug reactions. Ann Pharmacother 1992 Jul-Aug;26(7-8):890-6.

Campbell-Bright S, Gallelli, JF, Calis KA. Penicillin allergy and cephalosporin crossreactivity. Hosp Pharm 1992 Jun;27:540-1.

Calis KA, Kohler DR, Corso DM. Transdermally administered fentanyl for pain management. Clin Pharm 1992 Jan;11(1):22-36.

Kintzel PE, Calis KA. Recombinant interleukin-2: a biological response modifier. Clin Pharm 1991 Feb;10(2):110-28.

Calis KA, Grothe DR, Elia J. Attention-deficit hyperactivity disorder. Clin Pharm 1990 Aug;9(8):632-42.

Calis KA. Doctors and the dispensing of drugs. N Engl J Med 1987; 317(21):1354-5.

Calis KA, Mitsch RA. Sublingual use of benzodiazepines. Drug Intell Clin Pharm 1985 Nov;19(11):839-40.

### ABSTRACTS

Condarco TA, McDuffie JR, Brady S, Adeyemo L, Garcia R, Reynolds J, MD2, Hubbard VS, Calis KA, Yanovski JA (2014). Differences in Bone Turnover Markers and Bone Mineral Density in African-American and Caucasian Adolescents Taking Orlistat. *Endocrine Society Annual Meeting*, PX-XX.

Condarco T, Kazemzadeh R, et. al. (2013). Long-Term Follow-up of a Randomized, Placebo-Controlled Trial of Orlistat in African-American and Caucasian Adolescents with Obesity-Related Comorbid Conditions. *Endocrine Society Annual Meeting*, P.

Ranzenhofer, L., M. Tanofsky-Kraff, et al. (2008). "The Impact of Loss of Control (LOC) Eating on Adolescent Weight Loss in a Randomized Placebo-Controlled Medication Trial." *Obesity* 16: S129-S129.

Yanovski, J., J. McDuffie, et al. (2008). "A Randomized, Placebo-Controlled Trial of the Effects of Orlistat on Body Weight and Body Composition in African American and Caucasian Adolescents with Obesity-Related Comorbid Conditions." *Obesity* 16: S63-S63.

Yanovski, J., R. Sorg, et al. (2008). "Effects of Metformin on Body Weight and Body Composition in Children with Insulin Resistance: A Randomized, Placebo-Controlled Trial." *Obesity* 16: S63-S63.

Vaishali B Popat, Sophia N Kalantaridou, Vien H Vanderhoof, Karim A Calis, Lawrence M Nelson (2007). Effect of Long-Term Physiologic Transdermal Testosterone (150 mcg/Day) Replacement Therapy on Femoral Neck Bone Density in Women with Spontaneous Premature Ovarian Failure: Results of a 3-Year, Double-Blind, Placebo-Controlled Clinical Trial. *Endocrine Society Annual Meeting*, P1-349.

Sophia N Kalantaridou, Vien H Vanderhoof, Karim A Calis, Vaishali Popat, Vladimir K Bakalov, James F Troendle, Lawrence M Nelson (2007). Physiologic Transdermal Testosterone Replacement (150 mcg/Day) Does Not Significantly Improve Sexual Function in Women with 46,XX Spontaneous Premature Ovarian Failure: A Placebo-Controlled, Randomized Study. *Endocrine Society Annual Meeting*, OR27-4..

Vaishali B Popat, Vien H Vanderhoof, James F Troendle, Karim A Calis, Lawrence M Nelson (2006). Hormone Replacement Therapy in Young Women with 46, XX Spontaneous Premature Ovarian Failure Who Desire Fertility. *Endocrine Society Annual Meeting*, P2-546.

Loukas Gourgiotis, Caitlin Toomey, Gyorgy Csako, Frank Jr Pucino, Karim Calis, James Reynolds, Robert Wesley, Monica Skarulis, Giovanni Cizza (2006). Major Depressive Disorder (MDD) Is a Major Risk Factor for Osteoporosis: A Meta-Analysis of the Literature.

*Endocrine Society Annual Meeting, P3-524.*

Vaishali B Popat, Vladimir K Bakalov, Vien H Vanderhoof, Karim A Calis, James Reynolds, Nancy Sebring, James Troendle, Lawrence M Nelson (2006). Delay in Diagnosis and the Related Estrogen Deficiency Are Significantly Associated with Low Bone Mineral Density in 46, XX Spontaneous Premature Ovarian Failure. *Endocrine Society Annual Meeting, P3522.*

Vitaly Kantorovich, Vaishali B Popat, James Troendle, Smita Baid, Vien H Vanderhoof, Karim A Calis, Lawrence M Nelson (2006). Serum 1, 25 (OH)<sub>2</sub> Vitamin D Is Negatively Correlated with Bone Density Independent of 25-OH Vit D and PTH in Women with Spontaneous Premature Ovarian Failure. *Endocrine Society Annual Meeting, P3-520.*

Jennifer Elizondo, Margarita J Raygada, Allyn McConkie-Rosell, June Ventura, Vien H Vanderhoof, Karim A Calis, Vaishali Popat, Lawrence M Nelson (2006). FMR1 Premutation Testing Strategies in Women with Sporadic Spontaneous Premature Ovarian Failure: A Survey of Genetic Counselors. *Endocrine Society Annual Meeting, P3-541.*

Sophia N Kalantaridou, Karim A Calis, Vien H Vanderhoof, Vladimir K Bakalov, Donna H Peterson, Emily Corrigan, James Troendle, Lawrence M Nelson (2005). Transdermal Estradiol Therapy Significantly Reduces Serum Free Testosterone Levels in Young Women with Spontaneous Premature Ovarian Failure. *Endocrine Society Annual Meeting, P1-369.*

Pamela Slaughter, Teresa McHugh, Lisa B Yanoff, Amanda Spitalnik, Karim A Calis, Jack A Yanovski (2005). Relationship between Body Mass Index and Adherence To Study Medication in Overweight and Obese Adults. *Endocrine Society Annual Meeting, P1-737.*

Vladimir K Bakalov, Vien Vanderhoof, Karim A Calis, James Reynolds, Nancy Sebring, James Troendle, Lawrence M Nelson (2005). Prevalence of Osteoporosis and Low Bone Mineral Density in Young Women with Spontaneous Premature Ovarian Failure. *Endocrine Society Annual Meeting, P2-392.*

Vien H Vanderhoof, Kristen M Grabill, Karim A Calis, Emily C Corrigan, Donna M Peterson, Lawrence M Nelson (2005). Prevalence of Mood and Panic Disorder in Women with Spontaneous Premature Ovarian Failure as Detected by a Validated SelfAdministered Questionnaire. *Endocrine Society Annual Meeting, P3-541.*

Vien H Vanderhoof, Sophia N Kalantaridou, Karim A Calis, Vladimir K Bakalov, Emily C Corrigan, James F Troendle, Lawrence M Nelson (2005). Sexual Dysfunction in Young Women with Spontaneous Premature Ovarian Failure Persists Despite Physiological Estradiol Replacement. *Endocrine Society Annual Meeting*, P3-542.

Taylor ED, Tanofsky-Kraff M, Adler-Wailes D, Calis K, Ghorbani S, Mirch M, Theim K, Brady S, Yanovski JA (2005). Prevalence of orthopedic complications in overweight children and adolescents: A multi-dimensional cross-sectional analysis. *Journal of Bone and Mineral Research*, 20 (9), Suppl. 1, S101.

Taylor ED, Adler-Wailes D, Calis K, Ghorbani S, Tanofsky-Kraff M, Theim K, Brady S, Mirch, M, Yanoff L, Yanovski JA (2005). Orthopedic complications in overweight children and adolescents: DXA to assess lower extremity alignment. *Obesity Research*, 13, Suppl. S, A5-A6.

McDuffie J, Calis K, Oral E, Depaoli A, Yanovski J (2004). Effects of exogenous leptin on ghrelin and meal characteristics in patients with lipodystrophy. *Obesity Research*, 12, Suppl. S, A29.

Petraitis V, Petraitiene R, Lin P, Calis K, Kelaher AM, Murray HA, Mya-San C, Bacher J, Walsh TJ (2004). Comparison of the efficacy and safety of deoxycholate amphotericin B preparations in experimental invasive pulmonary aspergillosis. *Abstracts of the Interscience Conference on Antimicrobial Agents and Chemotherapy*, 44, M-226, p400.

Vanderhoof VH, Calis KA, Spitlanik AC, Sebring NG, Reynolds JC, Nelson LM. (2004) Osteoporosis-related health disparities in young women with premature ovarian failure. *Endocrine Society Annual Meeting*, 302, P1-587.

Yanoff LB, Parikh SJ, Edelman M, Denkinger B, Sebring NG, Slaughter P, McHugh T, Calis KA, Yanovski JA. (2004) Lower serum iron levels in obese subjects are not explained by lower iron intake. *Endocrine Society Annual Meeting*, 391, P2-348.

Eskandari F, Ronsaville D, Martinez PE, Torvik S, Kotila C, Mistry S, Sebring NG, Drinkard B, Calis KA, Reynolds J, Gold PW, Cizza G. (2004) Twenty-one to 45-year-old

premenopausal women suffering from major depression are at increased risk for osteopenia/osteoporosis. *Endocrine Society Annual Meeting*, 433, P2-508.

Pastor CL, Calis KA, Vanderhoof VH, Spitlanik AC, Premkumar A, Wesley RA, Guerrero NT, Lim LC, Nelson LM. (2004) Functional ovarian age is best reflected by a mathematical model employing basal FSH and FSH-stimulated inhibin B and estradiol levels. *Endocrine Society Annual Meeting*, 440, P2-535.

Spitlanik AC, Vanderhoof VH, Calis KA, Bakalov VK, Kalantaridou SN, Peterson DH, Wang BL, Nelson LM. (2004) Young women with 46,XX spontaneous premature ovarian failure are testosterone deficient and have significantly impaired sexual function. *Endocrine Society Annual Meeting*, 451, P2-575.

McDuffie, J; Calis, K; Rolls, B; et al. (2004) PROP taster status of obese adolescents is related to food ratings but not adiposity. *Obesity Research*, 12, Supplement S, PA95-A95.

Kantorovich V, Linday JR, Calis KA, Nieman L. (2004) Alternative uses for etomidate in ectopic Cushing's syndrome. *Endocrine Society Annual Meeting*, 455, P2-590.

Feuillan, P., Calis, K., Hill, S., Robey, P. G., & Collins, M. T. (2003). Letrozole treatment of precocious puberty in girls with the McCune-Albright Syndrome. *Pediatric Research*, 53(4), 136A-136A.

Parikh, S., Edelman, M., Semega-Janneh, M., Freedman, R., Calis, K., & Yanovski, J. (2003). Relationships between calcitropic hormones and measures of insulin sensitivity in overweight adults. *Diabetes*, 52, A293-A293.

Kurosawa, N., Owada, E., Calis, K.A., Daniels, C.E. (2002). Students' perceptions of a novel Japanese drug information core curriculum based on the NIH practice model. (Abstract). World Congress of Pharmacy and Pharmaceutical Sciences, *International Pharmaceutical Federation (FIP)*.

McDuffie JR, Nguyen T, Sastry L, McCann S, Hubbard VS, Calis K, Yanovski JA. (2002) A pilot study of the efficacy of orlistat in overweight adolescents. *First Annual Nutrition Week, San Diego*.

Calis, K. A. (2003). Reading the Biomedical Literature with a Critical Eye. *ASHP Midyear Clinical Meeting*, 38(Dec), PI-13.

Calis, K. A., Hansen, L. B., Boothby, L. A., & Carson, D. S. (2003). Journal Article Critique: Phytoestrogens for the Treatment of Hot Flashes. *ASHP Midyear Clinical Meeting*, 38(Dec), PI-14.

Calis, K. A., Max, B. E., Dong, B. J., & Kashuba, A. D. (2002). Journal Article Critique: Cessation of Antiretroviral Drug Therapy in HIV-Infected Patients. *ASHP Midyear Clinical Meeting*, 37(Dec), PI-13.

Calis, K. A. (2002). Critical Evaluation of the Biomedical Literature. *ASHP Midyear Clinical Meeting*, 37(Dec), PI-12.

Yanovski JA, McDuffie JR, McCann SM, Nicholson JC, Salaita CG, Calis KA. (2001) A pilot safety and efficacy study of orlistat for weight reduction in overweight adolescents. *Pediatric Endocrinology*.

McDuffie, J.R., Calis, K., Booth, S., Uwaifo, G.I., Yanovski, J.A. (2001) Effects of orlistat on fat-soluble vitamins in obese adolescents. *Obesity Research*, 9, 69S Suppl. 3 SEP 2001.

Charmandari E, Calis KA, Mohassel MR, Keil M, Chrousos GP, Merke DP. (2001) Flutamide decreases cortisol clearance: implications for therapy in congenital adrenal hyperplasia. *Endocrine Society Annual Meeting*, 457, P3-38.

Alzubaidi NH, Chapin HL, Vanderhoof VH, Calis KA, Nelson LM. (2001) Meeting the needs of young women with premature ovarian failure. *Endocrine Society Annual Meeting*, 593, P3-684.

Kurosawa, N., Ito, K., Calis, K. A., & Daniels, C. E. (2001). Development of a Drug Information Core Curriculum at Hokkaido College of Pharmacy Using the NIH Practice Model. *ASHP Midyear Clinical Meeting*, 36(Dec), INTL-52.

McCann,S., McDuffie,J., Nicholson,J., Sastry,L., Calis,K., Yanovski,J. (2000) A pilot study of the efficacy of orlistat in overweight adolescents. *Obesity Research*, 8, O179 Suppl. 1 OCT 2000.

Scott,B., Calis,K., Bergerson,S., Ognibene,F., Ford,D., Daniels,C. (2001) Evaluation of parenteral nutrition therapy at the NIH Clinical Center. *NIH Summer Research Program*, 39, 398.

Kalantaridou,S.N., Godoy,H., Malena,P.,Bickerton,G., Carmelli,K., Mazer,N., Kantartzis,S.N., Calis,K.A., Bondy,C., Nelson,L.M. (1999) Transdermal androgen replacement therapy for young women with spontaneous premature ovarian failure: a pilot study. *NIH Research Festival*, 42, I-6.

Kalantaridou,S.N., Calis,K.A., Godoy,H., Mazer,N.A., Bondy,C.A., Nelson,L.M. (2000) Transdermal testosterone replacement for young women with spontaneous premature ovarian failure: a pilot study. *Pharmacotherapy*, 20, No. 10, 1271, 268E.

Padmanabhan H, Patel SC, Calis KA, Bondy CA, Nelson LM. (2000) Nonalcoholic steatohepatitis: a possible feature of polycystic ovary syndrome. *Endocrine Society Annual Meeting*, 1676, 430.

Krakoff J, Koch CA, Calis KA, Nieman LK. (2000) Use of a propylene glycol-containing etomidate preparation for the long-term management of ectopic Cushing's Syndrome. *Endocrine Society Annual Meeting*, 1933, 453.

Kalantaridou,S.N., Calis,K.A., Godoy,H., Mazer,N.A., Bondy,C.A., Nelson,L.M. (2000) Transdermal testosterone replacement for young women with spontaneous premature ovarian failure: a pilot study. *Endocrine Society Annual Meeting*, 2322, 572.

Weil SJ, Patel SC, Calis KA, Bondy CA, Nelson LM. (2000) Clomiphene-resistant hyperandrogenic anovulation. *Endocrine Society Annual Meeting*, 2337, 606.

Patel SC, Pastor CL, Calis KA, Bakolov VK, Bondy CA, Nelson LM. (2000) A pilot trial of flutamide in clomiphene-resistant hyperandrogenic anovulation. *Endocrine Society Annual Meeting*, 2341, 610.

Abassi,Z.A., Pieruzzi,F., Calis,K., Klein,H., Keiser,H.R. (1994) Effects of cyclosporine on the clearance of labeled endothelin in rats. *Journal of the American Society of Nephrology*, 5, 598.

- Calis,K.A. (2001) Hormone/estrogen replacement therapy update. (Abstract). *ASHP Annual Meeting*, 58, PI-49.
- Calis,K.A., Ponte,C.D., McPherson,M.L., Koda-Kimble,M.A. (2001) Journal article critique: insulin glargine vs NPH insulin for type 2 diabetes. (Abstract). *ASHP Midyear Clinical Meeting*, 36, PI-160.
- Calis,K.A. (2001) Critical reading of the biomedical literature. (Abstract). *ASHP Midyear Clinical Meeting*, 36, PI-159.
- Kurosawa,N., Ito,K., Calis,K.A., Daniels,C.E. (2001) Development of a drug information core curriculum at Hokkaido college of pharmacy using the NIH practice model. (Abstract). *ASHP Midyear Clinical Meeting*, 36, INTL-52.
- Calis,K.A. (2000) Concepts in the analysis of drug efficacy and safety. (Abstract). *ASHP Midyear Clinical Meeting*, 35, PI-8.
- Heck,A.M., Turcasso,N.M., Harper,M.L., Calis,K.A. (2000) Interpreting the pharmacotherapy literature: journal article critique. (Abstract). *ASHP Midyear Clinical Meeting*, 35, PI-10.
- Mohassel,M.R., Calis,K.A., Merke,D.P., Keil,M., Remaley,A.T. (1999) Effects of flutamide and testolactone on cortisol clearance in children with congenital adrenal hyperplasia. *Pharmacotherapy*, 19, No.10, 1201, 54.
- Calis,K.A., Heck,A.M., Young,L.R., Mohassel,M.R. (1998) Algorithm for detecting, evaluating, and managing potential drug interactions. (Abstract). *ASHP Midyear Clinical Meeting*, 33, P-98D.
- Calis,K.A. (1997) Role of the Internet in contemporary practice. (Abstract). *ASHP Midyear Clinical Meeting*, 32, PI-70.
- Young,L.R., Calis,K.A., Heck,A.M., Blankenship,C.S. (1997) Algorithm for evaluating and managing potential adverse drug events. (Abstract). *ASHP Midyear Clinical Meeting*, 32, P77D.
- Calis,K.A. (1996) Importance of trial design to application of information. (Abstract). *ASHP Midyear Clinical Meeting*, 31, PI-30.



Calis,K.A., Young,L.R., Masucci,I.P. (1996) Algorithm for managing compatibility of parenteral medications. (Abstract). *ASHP Midyear Clinical Meeting*, 31, P-34D.

Young,L.R., Calis,K.A., Plante,M.L. (1996) Algorithm for the management of drug extravasations. (Abstract). *ASHP Midyear Clinical Meeting*, 31, P-124D.

Calis,K.A., Mays,D.A. (1995) Pharmacotherapy related information resources accessible via the Internet. (Abstract). *ASHP Midyear Clinical Meeting*, 30, P-170(D).

Turcasso,N.M., Auth,D.A., Calis,K.A., Anderson,D.W., Mays,D.A., Meyer,C.C. (1995) Survey of drug information centers for characteristics that may serve as quality indicators. (Abstract). *ASHP Midyear Clinical Meeting*, 30, P-343(D).

Young,L.R., Calis,K.A. (1995) Clinically oriented drug information residency training. (Abstract). *ASHP Midyear Clinical Meeting*, 30, RTP-24.

Calis,K.A., Lifshin,L.S., Mowery,D., Robinson,H. (1992) WMSHP: twenty-eight years of excellence. (Abstract). *ASHP Midyear Clinical Meeting*, 27, ASC-21.

Calis,K.A. (1992) Use of computer data bases in clinical pharmacy practice. (Abstract). *ASHP Midyear Clinical Meeting*, 27, PI-135.

DeLeo,J.M., Calis,K.A., Dorworth,T.E., Pucino,F. (1991) Portable patient-entry medication history computer system. (Abstract). *ASHP Annual Meeting*, 48, P-153D.

DeLeo,J.M., Pucino,F., Calis,K.A. (1991) Computer-learned adverse drug reaction detection. (Abstract). *ASHP Annual Meeting*, 48, CR-3.

Calis,K.A., Marchand,H.C. (1988) Documenting pharmacists' clinical interventions using a hospitalwide quality assurance computer network. (Abstract). *ASHP Midyear Clinical Meeting*, 23, MCS-32.

Calis KA, Rodriguez de Bittner M. (1986) Evaluation of Surgical antimicrobial prophylaxis. (Abstract) *ASHP Midyear Clinical Meeting*.

#### **OTHER PUBLICATIONS & PRODUCTIONS**

Online course developed as part of a DHHS advisory committee: *Preventing Adverse Drug Events: Individualizing Glycemic Targets Using Health Literacy Strategies* accessible at [http://www.health.gov/hai/training.asp#prevent\\_ades](http://www.health.gov/hai/training.asp#prevent_ades)), 2014

Csako G, Pucino F, Calis KA. Book Review: *Stockley's Drug Interactions*. By Karen Baxter, Pharmaceutical Press, UK, 2008. *Ann Pharmacother* 2008.

McGriff-Lee N, Calis KA. *Guide to Hormone Therapy*. OB/GYN Special Edition 2003;6:19-22.

Dang DK, Pucino F, Calis KA. Book Review: *Complementary Therapies for Pharmacists*, By Steven B. Kayne, Pharmaceutical Press, London, UK, 2002. ISBN 0-85369-430-3. *Journal of Natural Products*, 2002.

Calis KA, Pastor CL. Book Review: *Rewinding Your Biological Clock—Motherhood Late in Life*. By Richard L. Paulson and Judith Sachs, W. H. Freeman and Company, New York, NY, 2000. *Am J Health-Syst Pharm* 2001; 58: 828.

Calis KA, Herbst SL, Sidawy EN. *Management of central venous catheter occlusions: the emerging role of alteplase*. Cheshire, England: Gardiner-Caldwell SynerMed, 1999; 1-16. [ACPE-accredited continuing education monograph]

Calis KA. *The use of alteplase to treat central venous catheter occlusions*, *Current Concepts in Regional Thrombolysis and Catheter Clearance*, Society for Cardiovascular and Interventional Radiology, October 5, 1999. [CME cyberprogram and website slide show]

Calis KA. *Pharmacology of alteplase*, *Current Concepts in Regional Thrombolysis and Catheter Clearance*, Society for Cardiovascular and Interventional Radiology, October 5, 1999. [CME cyberprogram and website slide show]

Calis KA, Daniels CE. *Secretin available under FDA treatment protocol*. *Am J Health-Syst Pharm* 2002;59:198.

Meyer CC, Calis KA. *More information on vancomycin clearance by new hemodialysis membranes*. *Am J Health-Syst Pharm* 1996;53:1339-40+48.

Calis KA, Pucino F. Pharmacotherapeutic misadventures. Preventing Medication Misadventures. Dialogues in Hospital Pharmacy, Cortlandt Communications, 1996. [Videotape educational program, Vol. 2, No. 2.]

Kohler DR, Calis KA, Corso DM. Value of transdermal fentanyl. Clin Pharm 1992;11: 584-5.